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Human health and ecological risk assessors are currently facing increased demands and 
public pressure to evaluate the potential risk of hundreds to thousands of chemicals based 
on limited toxicity data.  Therefore, scientifically sound models are needed to predict 
toxicity without sole reliance on conventional whole-organism (vertebrate) bioassays.  To 
help address this challenge, adverse outcome pathways (AOPs) have recently been 
proposed as conceptual tools to help link direct, molecular-level initiating events to 
adverse outcomes at higher levels of biological organization. Additionally, using AOPs 
as frameworks, high-throughput screening (HTS) and high-content screening (HCS) 
assays have been recently proposed as key components of a tiered regulatory toxicity 
testing strategy that enables screening and prioritization of chemicals for further testing 
using conventional bioassays. Therefore, using zebrafish embryonic development as a 
model, the overall research aims of this dissertation were to 1) rely on paraoxon – the 
active metabolite of the organophosphorus (OP) insecticide parathion – as a reference 
acetylcholinesterase (AChE) inhibitor to examine whether the common molecular 
initiating event (AChE inhibition) was associated with adverse neurological effects at 
higher levels of biological organization and 2) develop and optimize a HCS assay to 
identify chemicals impacting cardiovascular function and potentially serve as a platform 
for guiding AOP discovery and development. Data presented within Chapter 1 suggests 
that (1) normal AChE activity is not required for secondary motoneuron development and 




paraoxon exposure, an effect that may be independent of AChE inhibition. Data 
presented within Chapter 2 suggests that, compared to existing zebrafish-based assays, 
our HCS assay provides a comprehensive chemical screening and AOP discovery 
platform with 1) increased sample sizes; 2) broad concentration-response format; and 3) 
the ability to identify chemicals that target cardiovascular function at non-teratogenic 
concentrations. Overall, this dissertation highlights the scientific and logistical challenges 
in developing quantitative AOPs to support chemical screening and prioritization 
strategies. Nonetheless, qualitative AOPs can play a role in identification of HTS/HCS 
assays that capture key events along an AOP, and results of HTS/HCS-based chemical 
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1.1 INTRODUCTION TO ADVERSE OUTCOME PATHWAYS (AOPS) 
Human health and ecological risk assessors are currently facing increased 
demands and public pressure to evaluate the potential risk of hundreds to thousands of 
chemicals based on limited toxicity data.  Therefore, scientifically sound models are 
needed to predict toxicity without solely relying on conventional whole-organism 
(vertebrate) bioassays.  To address this challenge, the Organization for Economic Co-
operation and Development (OECD) recently issued a guideline on developing and 
assessing adverse outcome pathways (AOPs) (OECD, 2012). AOPs have been proposed 
as conceptual frameworks to link direct, molecular-level initiating events to adverse 
outcomes at higher levels of biological organization (Ankley et al., 2010). The AOP 
approach is based on the notion that a toxic effect results from a chemical interacting 
with an initial target and that this interaction cascades into key events that ultimately 
result in an adverse outcome (OECD, 2012) (Figure 1.1). These adverse outcomes must 
occur at a biological level relevant to regulatory decisions (Ankley et al., 2010), and if 
not, are defined as a key event (OECD, 2012). A ‘bottom-up’ approach is often applied to 
develop an AOP, where the chemistry and mode of action (MOA) are initially used to 
hypothesize key events and the adverse outcome (OECD, 2012). On the other hand, a 
‘top-down’ approach can be utilized by assessing the adverse outcome to formulate 





Currently, there is an effort and interest in building and annotating qualitative 
AOPs, where data is gathered from the literature to predict toxicological effects across 
multiple levels of biological organization. However, these linkages are difficult to 
determine due to differences in dose-response characteristics among these levels. Thus, 
quantitative linkages between levels of biological organization need to be established. 
Using a battery of reference chemicals with known MOAs and mechanisms of toxicity 
can help in developing these quantitative AOPs. Once described and annotated, AOPs 
can be used to identify alternative, high-throughput predictive assays and testing 
strategies that help inform risk assessments, as well as facilitate identification of 
uncertainties and corresponding research gaps.  Moreover, linked with computational 
tools for concentration-response extrapolation across multiple levels of biological 
organization, these alternative assays, once developed and validated, will likely provide 
flexibility in testing based on risk-management needs while, at the same time, reduce 
animal use and study costs (NRC, 2007). 
 
1.2 THE NEED FOR HIGH-THROUGHPUT/HIGH-CONTENT SCREENING (HTS/HCS) ASSAYS  
Chemical use and migration from end-use products to indoor and outdoor 
environments poses a potential risk for humans and ecosystems. Due to these concerns, 
whole-organism toxicity test guidelines standardized and issued by the OECD are used to 
support human health and ecological risk assessments around the world. Even though 
whole-organism toxicity data are not currently required for pre-market approval of 
chemicals regulated under the Toxic Substances Control Act (TSCA) within the United 





the demand for generating toxicity data across multiple species and hundreds to 
thousands of registered and new chemicals in commerce. As of today, safety information 
for over 83,000 chemicals registered under the TSCA is limited and, in most cases, 
unknown. Currently, the Environmental Protection Agency (EPA) uses quantitative 
structure-activity relationships (QSAR) and ecologically structure-activity relationships 
(ECOSAR) models to determine the hazards of these registered chemicals, and toxic 
effects of a newly registered chemical are predicted by relying on structural attributes, 
physicochemical properties, and potential metabolites that can be easily determined. 
However, this type of testing is not always predictive when determining the potential 
toxicity of each chemical. Moreover, a chemical registrant must notify the EPA of their 
intention to manufacture a new chemical. The EPA then has 90 days to block the 
manufacture of this chemical, or it can be legally marketed without any additional 
toxicity tests. With the proposed amendments to TSCA to require toxicity tests and 
continued registration and re-registration of pesticides under the Federal Insecticide, 
Fungicide, and Rodenticide Act (FIFRA), there will likely be a significant increase in 
demand to use whole-organism guideline toxicity tests. These guideline tests are not only 
costly and animal-intensive, but also provide minimal information about chemical MOA 
due to a principal focus on apical endpoints such as survival, development, and 
reproduction.  
Around the world, there is an intense effort and vested interest in reducing animal 
usage. European countries have taken the lead on this effort, and the Registration, 
Evaluation, Authorization, and Restriction of Chemical Substances (REACH) regulation 





of human health and the environment through the better and earlier identification of the 
intrinsic properties of chemical substances” (REACH, 2010). Similar to the EPA, 
chemical manufacturers are required to collect and submit safety data for evaluation by 
regulatory authorities; furthermore, REACH requires that these data be shared among 
registrants to avoid unnecessary animal testing (REACH, 2010). One goal of REACH is 
to replace, reduce, and refine the use of animals in scientific procedures, thus a 
replacement to whole-animal testing must always be considered first.  When an 
alternative is not possible, reduction alternatives (fewer animals are used) and refinement 
alternatives (methods that cause the least pain and suffering) are used (REACH, 2010). 
Therefore, due to the limitations of whole-organism toxicity tests and the interest in 
reducing animal usage, resource-efficient alternatives such as high-throughput and high-
content screening assays have been proposed as key components of a future testing 
strategy for regulatory toxicology and ecotoxicology (Andersen and Krewski, 2009; 
Bradbury et al., 2004; NRC, 2007; Villeneuve and Garcia-Reyero, 2011).   
 
1.3 ADVANCEMENTS IN HIGH-THROUGHPUT ASSAYS 
 Although high-throughput screening (HTS) assays have long been used by the 
pharmaceutical and pesticide industry to help prioritize lead candidates during early-stage 
product development, the potential application of these assays for regulatory toxicology 
is a relatively recent development. The purpose of these screens is to discover active 
compounds that elicit an effect on a chemical pathway with the ultimate goal of helping 
to identify the MOA. The term “high-throughput” is relative to the assay – it can range 





As of today, safety information for thousands of chemicals in commerce is 
unknown. It is unrealistic and costly to test this large quantity of compounds using 
traditional, whole-organism/in vivo methods, so cell lines/in vitro methods are often used 
as the first tier of a tiered testing strategy. Although in vitro models do not provide the 
physiological context and are difficult to extrapolate to whole organisms, these models 
simplify exposure protocols, reduce the amount of test material needed, and allow for 
identification of chemicals that interact with specific receptors, proteins, or other 
molecules without the possibility of off-target effects.  Nonetheless, the exploration and 
use of in vivo models for HTS assays is currently on the rise as a second tier to examine 
the interactions of a compound and a whole organism.  
 
1.3.1 CURRENT USE OF HIGH-THROUGHPUT SCREENING (HTS)/ HIGH-CONTENT 
SCREENING (HCS) 
 Due to advancements in technology and HTS/HCS methods, the use of these 
methods has been on the rise. The National Institute of Health (NIH) is currently using 
HTS assays as part of a relatively new toxicity testing strategy developed from the 2007 
National Toxicology Program’s (NTP) “Vision and Roadmap for the 21st Century” 
(Schmidt, 2009). As traditional toxicity tests are low-throughput, expensive, and use a 
high number of animals, HTS/HCS methods are being utilized with the goal of moving 
from an observational science at the level of disease-specific models to a predictive 
science focused on target-specific and mechanism-based observations. In fact, the 
toxicity testing paradigm is beginning to shift towards more high-throughput methods 





currently do not have any toxicity data (Schmidt, 2009). Currently, the NTP uses HTS 
assays to: 1) prioritize substances for further, in-depth evaluation; 2) identify the MOA; 
and 3) develop predictive models for in vivo biological response.  
In 2008, to gain support for this shift in the toxicity testing paradigm, the NTP 
entered into a five-year partnership, known as Tox21, with the EPA’s National Center for 
Computational Toxicity (NCCT), and the National Human Genome Research Institute’s 
NIH Chemical Genomics Center (NCGC), in which the NTP, NCCT, and NCGC have 
expertise in experimental toxicology, computational toxicology, and high-throughput 
technologies, respectively (Schmidt, 2009). The U.S. Food and Drug Administration 
(FDA) was later added into the partnership and brought the expertise of human diseases 
and animal models of human disease, as well as toxicity pathway analysis and 
computational toxicology.  
Within Phase I of the Tox21 initiative, each partner screened hundreds to 
thousands of chemicals with HTS assays. The NCGC screened 2800 compounds in more 
than 50 quantitative HTS (qHTS) assays using a 1536-well microtiter plate to test as 
many as 15 concentrations per compound, allowing for concentration-response curves to 
be generated. These concentration-response curves may provide better and more 
information about low-dose human effects compared to traditional toxicity tests 
(Schmidt, 2009). Using robots, the NCGC can process 100 plates per day, resulting in 
over one million samples per week. Concurrently, the NCCT was screening 309 
compounds in more than 500 biochemical- and cell-based assays in the ToxCast™ 
program that uses a multiple matrix approach, including in silico models, biochemical 





Parallel to other screens, the NTP tested the same 309 compounds on Caenorhabditis 
elegans in the WormTox program. Within Phase II, the goal is to identify a full spectrum 
of secondary and tertiary screening assays that will then be used to further define and 
characterize activities identified in the initial screening process (Schmidt, 2009). The 
Tox21 partners will test 10,000 compounds using the facilities at NCGC. Additionally, 
the NCCT will test 700 compounds in ToxCast™. While in vitro and cell-based assays 
may not provide the complex interactions that in vivo models offer, these assays do 
provide a rapid first-tier screening system to identify chemicals of interest to test using 
other alternative animal models like C. elegans or zebrafish. 
 
1.3.2 ALTERNATIVE ANIMAL MODELS CURRENTLY USED IN HTS/HCS ASSAYS 
 Certain characteristics of traditional animal models (e.g., mice and rats) – 
including high husbandry costs, large size, and difficulties with non-invasive imaging – 
preclude the ability of these models to be used for HTC/HCS assays. Therefore, the use 
of alternative animal models, including C. elegans, Drosophila melanogaster (fruit fly), 
and Danio rerio (zebrafish) for HTS/HCS assays are on the rise. Numerous 
characteristics make C. elegans an appropriate model for HTS/HCS assays and toxicity 
tests including a rapid life cycle, high fecundity, transparency throughout all life stages, 
and small size. The life cycle of C. elegans has been studied and reviewed extensively 
(Corsi, 2006; Leung et al., 2008). Embryogenesis is a rapid, 13-hour cycle that begins 
with in utero development until gastrula stage (30 cells) when the egg is laid and ex utero 
development commences. After hatching, the larvae develop through four different stages 





hermaphroditic organisms, C. elegans are able to produce hundreds of genetically 
identical offspring, which is advantageous for genetic screens (Hope, 1999). Due to the 
small and transparent body, automated pipetting systems and high-throughput imaging 
methods relying on absorbance, fluorescence, movement, and morphology have been 
developed (Baek et al., 2002; Boyd et al., 2010; Giacomotto and Segalat, 2010; Gosai et 
al., 2010). In fact, these nematodes have been used in many high-throughput assays to 
estimate the toxicity of chemicals on several endpoints including growth and 
reproduction (Boyd et al., 2010; Gosai et al., 2010). Additionally, the genome is well 
annotated within WormBase (http://www.wormbase.org), an online and public reference 
tool with information about the genetics, genomics, and biology of C. elegans (Harris et 
al., 2004). Forward genetic techniques can also be utilized to understand the role of 
different genes in mediating toxicity (Leung et al., 2008). Most importantly, many 
biological pathways and stress responses seen in higher-level organisms are conserved in 
C. elegans (Leung et al., 2008); however, some diseases cannot be modeled within C. 
elegans because of a lack of homologous genes or organs (Giacomotto and Segalat, 
2010), limiting the utility of these worms.  
 The fruit fly (D. melanogaster) was first used in the early 1900s as a genetic 
model, but has evolved into an intensely studied model organism not only for genetics 
but also in other areas including behavior, locomotion, and development (Branson et al., 
2009; Dankert et al., 2009; Jakubowski et al., 2012; Peng et al., 2007). Similar to C. 
elegans, numerous characteristics make the fruit fly an appropriate model for HTS/HCS 
assays and toxicity tests including rapid development, high fecundity, transparent 





and continue to grow, molting at 24 and 48 hours before encapsulating themselves in a 
paparium on day four. The larvae then undergo four days of metamorphosis, and emerge 
as adult flies. D. melanogaster females can produce 100 eggs per day and have a short 
generation time (~10 days), allowing for several generations to be studied within a few 
weeks (Giacomotto and Segalat, 2010). Additionally, the genome was first published in 
2000 (Adams et al., 2000) and is available via FlyBase (http://www.flybase.org), an 
interactive online tool in which investigators can search for genetics, phenotypes, 
sequences, stocks, and other information. Importantly, more than 60% of human genes 
have functional orthologs within the fly (Reviewed in Giacomotto and Segalat, 2010), 
which make this organism an important model in examining human diseases. The fly, 
however, can not be grown in aqueous medium, limiting its uses in HTS/HCS studies and 
drug screens. However, recent technological advancements have made HTS/HCS assays 
using this fly possible. For example, D. melanogaster has been recently used in 
HTS/HCS methods to identify the genes responsible for adverse crawling behavior 
(Jakubowski et al., 2012) and drugs that modify food intake (Gasque et al., 2013). The 
use of Drosophila for studies other than genetics is on the rise. 
 
1.4 ZEBRAFISH AS AN ALTERNATIVE ANIMAL MODEL 
While zebrafish, medaka, and rainbow trout have long been used as models for 
developmental biology, genetics, and toxicology, zebrafish are the preferred fish model 
for human disease (Lieschke and Currie, 2007), high-throughput drug discovery (Zon and 
Peterson, 2005), and chemical toxicity screening (Hill et al., 2005).  Zebrafish are often 





(worm and fly) to mammals (mouse and human) (Giacomotto and Segalat, 2010). 
Numerous characteristics make the zebrafish a suitable model for toxicity screening 
including rapid, ex utero development, high fecundity, transparency during 
embryogenesis, and small size. Moreover, relative to larger animal models like rodents 
and rainbow trout, zebrafish colony maintenance requires minimal start-up investments, 
annual operational costs, personnel labor, and laboratory space.  
Zebrafish embryogenesis is rapid (72 h from fertilization to hatch) and comprised 
of seven developmental periods: zygote (0-0.75 hpf), cleavage (0.75-2.25 hpf), blastula 
(2.25-5.25 hpf), gastrula (5.25-10 hpf), segmentation (10-24 hpf), pharyngula (24-48 
hpf), and hatching (48-72 hpf) (Kimmel et al., 1995). Females can produce hundreds of 
embryos each day, which is beneficial for high-throughput assays and provides 
statistically significant sample sizes at a low cost. Transparent embryos also allow for the 
use of transmitted light or fluorescence to assess gross morphology as well as multiple 
organs such as the liver, heart, and nervous system. Additionally, since embryos develop 
ex utero, developmental toxicity can be easily assessed since small hydrophobic 
compounds (log Kow > 2) can be either directly absorbed by the embryo and larger 
and/or hydrophilic compounds can be microinjected into the embryo during development. 
The zebrafish embryo is approximately 1 mm in diameter and can survive in a 96-well 
plate until 7 days post-fertilization (dpf) (McGrath and Li, 2008). Other important 
characteristics of zebrafish are: (1) the genome is fully sequenced; (2) developing 
embryos can be genetically altered with ease, which can help identify important genes 
that regulate specific responses to compounds; and (3) a number of compounds elicit 





zebrafish are almost 100% similar to that of humans (Langheinrich, 2003). Nevertheless, 
a few disadvantages of using the zebrafish model in HTS/HCS assays include the limited 
number of transgenic lines that produce high numbers of viable embryos and a lack of 
appropriate tools to manipulate and analyze the copious amounts of data associated 
HTS/HCS assays. Despite these limitations, the zebrafish model is a valuable and 
increasingly used model for HTS/HCS assays. 
The advantages associated with using zebrafish have led to the use of zebrafish-
based developmental toxicity assays to evaluate the potential human health hazards of 
960 unique chemicals within EPA’s ToxCast™ program.  In this assay, wildtype 
zebrafish are continuously exposed to individual chemicals in 96-well plates from ~8 
hours post-fertilization (hpf) (late gastrula) to 5 days post-fertilization (dpf), and then 
manually evaluated for mortality and gross malformations at 6 dpf (Padilla et al., 2012). 
Following identification of positive chemicals from single-concentration limit tests (e.g., 
at 80 µM), multiple concentrations are tested to define the slope, median effective 
concentration (EC50), and no-observable effect concentration (NOEC) of the 
concentration-response curve.  Although these types of assays are valuable for identifying 
teratogenic and acutely lethal chemical concentrations, gross malformation-based 
endpoints such as pericardial edema, body curvature, and craniofacial abnormalities often 
lack chemical specificity, providing little to no information about the mechanism of 
toxicity (molecular-level initiating event) and mode-of-action (key events leading to 
disruption of organogenesis).  Therefore, in order to enhance EPA’s existing zebrafish 
embryo assays within ToxCast™, functional zebrafish-based assays are needed to better 





relevant AOPs. For example, the HCS assay discussed in Chapter 3 of this dissertation 
enhances the ToxCast™ zebrafish embryo assay by providing a functional zebrafish-
based assay that can evaluate targeted effects on angiogenesis and cardiovascular 
development as well as classify chemicals by toxicologically relevant AOPs. 
 
1.4.1 ZEBRAFISH AS A MODEL FOR NERVOUS SYSTEM DEVELOPMENT 
 The nervous system of zebrafish has been studied extensively over the last 25-30 
years (Hjorth and Key, 2002; Kuwada et al., 1990; Myers et al., 1986). First, the 
transparency of the zebrafish embryo allows for observation of the growing brain, 
notochord, and spinal cord. Additionally, transgenic lines such as Tg(nkx2.2a:mEGFP) 
make live imaging of the nervous system possible, and immunohistochemistry techniques 
can be used to label many aspects of the nervous system within fixed individuals. The 
nervous system is fully functional by 24 hpf, thus screening chemicals to investigate 
effects on the nervous system can be completed quickly after initiation of exposure 
following fertilization. Zebrafish have been also been utilized to assess locomotion 
(Downes and Granato, 2004; Thomas et al., 2009) and, more recently, neurodegenerative 
diseases (Fitzmaurice et al., 2013), all of which are directly related to successful 
development of the nervous system. Finally, since the zebrafish genome is fully 
sequenced, zebrafish can be used to examine the genes required for normal nervous 
system development and which genes are affected when the organism is exposed to 
neurotoxic compounds (Kluver et al., 2011).  
Primary neurogenesis within the zebrafish, unlike other vertebrates, begins during 





in the neural plate (Blader and Strahle, 2000; Hjorth and Key, 2002; Kimmel et al., 
1995). The primary motoneurons first appear on the ventral floor of the spinal cord and 
migrate to their final destination within the spinal segments by 16 hpf (Myers et al., 
1986). By 18 hpf, the anterior neural tube and the posterior neural tube develop into ten 
brain neuromeres and the spinal cord, respectively (Kimmel, 1993). Additionally, the 
primary interneurons differentiate and establish axon tracts that extend within each brain 
neuromere and spinal cord segment (Myers et al., 1986; Wilson et al., 1990). The primary 
motoneurons then innervate the surrounding muscle fibers in a highly categorized, error-
free method (Hanneman et al., 1988; Myers et al., 1986), initiating the first movements of 
the developing embryo – weak, spontaneous muscle contractions (Kimmel et al., 1995; 
Myers et al., 1986). Subsequently, secondary motoneurons develop 5-6 hours after 
development of the primary motoneurons (Myers et al., 1986). By 24 hpf, a fully 
functional neural circuit is complete.  
 
1.4.2 ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR DEVELOPMENT 
During the past decade, zebrafish have been examined as a potential model 
organism for cardiovascular development. The zebrafish develops very rapidly with the 
heart and vascular systems being fully functional by 48 hpf. Secondly, zebrafish 
development is not dependent on a functional cardiovascular system (Bakkers, 2011; 
Isogai et al., 2001). Unlike avian and mammalian models, zebrafish embryos can survive 
on passive diffusion of oxygen, making it possible to examine severe cardiovascular 
defects (Bakkers, 2011). Third, contrary to mammalian models, the transparency of the 





cardiovascular system to be studied during early vascular development within live 
animals (Bakkers, 2011). Lastly, since the zebrafish genome is fully sequenced, it is 
possible to conduct forward genetic screens to identify genes responsible for normal 
cardiovascular development as well as reverse genetic approaches to examine the role 
and function of genes during development.  
The heart is the first functional organ system of the vertebrate embryo (Flamme et 
al., 1997); in fact, the heart begins to form within zebrafish during the gastrula period 
(5.25-10 hpf) with the specification of the myocardial and endocardial progenitor cells 
(Bakkers, 2011). Cardiac differentiation is then initiated by 16 hpf (Bakkers, 2011), and 
the tube heart is lumenized and beating commences by approximately 22-25 hpf (Stainier 
et al., 1993). By 36 hpf, the heart begins to loop towards the right lateral side (Stainier et 
al., 1993) and is complete by 48 hpf (Glickman and Yelon, 2002) with the atrium and 
ventricle located to the left and right of the midline, respectively, when orientated in 
dorsal recumbency.  
The heart is not the only organ growing during this window of development; the 
vascular system is also beginning to evolve. Angioblasts first appear within the posterior 
lateral plate mesoderm of the trunk at 12 hpf (Jin et al., 2005). By 20 hpf, arterial- and 
venous-fated angioblasts begin to aggregate at the midline and form a vascular cord that 
becomes lumenized (dorsal aorta (DA) primordium) by 22 hpf (Herbert et al., 2009). 
Venous-fated angioblasts then sprout ventrally from the DA primordium and merge 
around resident blood cells forming the lumenized caudal vein (CV) primordium by 26 
hpf (Herbert et al., 2009). By 30 hpf – several hours after the heart begins to beat – 





(Herbert et al., 2009; Isogai et al., 2001). Unlike many vertebrates, the DA and PCV 
within zebrafish are single, unpaired tubes when circulation commences in the trunk 
(Isogai et al., 2001). By 36 hpf, the intersegmental vessels (ISV) begin to sprout and 
elongate dorsally from the DA and PCV (Isogai et al., 2001). The ISVs then form a “T” 
shape in the most dorsal region of the trunk and extend longitudinally to form the dorsal 
longitudinal anastomotic vessels (DLAVs) (Childs et al., 2002; Isogai et al., 2001). By 48 
hpf, the ISVs are lumenized and possess active circulation (Isogai et al., 2001), and the 
majority of the cardiovascular system development is complete. Many studies suggest the 
development of the vascular system within zebrafish is similar to other vertebrates 
including humans and can be used as a model for human cardiovascular development and 
health.  
 
1.5 RESEARCH OBJECTIVES 
As discussed above, scientifically sound models are needed to predict toxicity 
without sole reliance on conventional whole-organism (vertebrate) bioassays.  To help 
address this challenge, AOPs have recently been proposed as conceptual tools to help link 
direct, molecular-level initiating events to adverse outcomes at higher levels of biological 
organization. Additionally, using AOPs as frameworks, HTS/HCS assays have been 
recently proposed as key components of a tiered regulatory toxicity testing strategy that 
enables screening and prioritization of chemicals for further testing using conventional 
bioassays. Therefore, using zebrafish embryonic development as a model, the overall 
research objectives of this dissertation were to 1) rely on paraoxon – the active metabolite 





(AChE) inhibitor to examine whether the common molecular initiating event (AChE 
inhibition) was associated with adverse neurological effects at higher levels of biological 
organization and 2) develop and optimize a HCS assay to identify chemicals impacting 
cardiovascular system function and potentially serve as a platform for guiding AOP 


















ADVERSE OUTCOME PATHWAYS DURING ZEBRAFISH EMBRYOGENESIS: A CASE STUDY  
WITH PARAOXON 
2.1 INTRODUCTION 
As fish embryos (pre-hatch stages) and eleuthereoembryos – the time-period 
between immediately post-hatch and independent feeding – are non-protected life-stages, 
these early life-stages are considered alternative testing models within the European 
Union and United States (Belanger et al., 2010; Embry et al., 2010; Halder et al., 2010; 
Scholz et al., 2008).  In contrast to cell-based assays, fish embryos provide the 
complexity and interaction of an intact organism, enabling the evaluation of adverse 
chemical effects on multiple target organs and developmental stages during 
embryogenesis. To begin testing the feasibility of developing alternative AOP-based 
assays, the objective of this study was, using a well-studied reference chemical, to 
develop an AOP that provided quantitative linkages across levels of biological 
organization during zebrafish embryogenesis.  
Organophosphorus (OP) insecticides are used for broad-spectrum insect control 
on ornamentals, turf grass, and certain vegetable and field crops. These insecticides are 
potent acetylcholinesterase (AChE) inhibitors that induce cholinergic toxicity via 
acetylcholine (ACh) accumulation and activation of acetylcholine receptors (AChR) 





target adverse effects on humans (in particular children), the use of OP insecticides for 
indoor applications was eliminated in the United States in 2000-2001 (U.S. EPA, 2000; 
U.S. EPA, 2001). For this study, we relied on paraoxon – the active metabolite of the OP 
insecticide parathion – as a reference acetylcholinesterase (AChE) inhibitor to examine 
whether the common molecular initiating event (AChE inhibition) was associated with 
adverse neurological effects at higher levels of biological organization. Although two 
previous studies have assessed the potential effects of paraoxon exposure on AChE 
activity and development of 48-hpf zebrafish embryos (Kuster, 2005; Kuster and 
Altenburger, 2006), these studies did not examine potential neurological effects within 
later stages of embryogenesis (>48 hpf) nor assess recovery of AChE activity.  As 
zebrafish do not have butyrylcholinesterase (BChE) (Bertrand et al., 2001), we first 
characterized the magnitude of ache expression at multiple stages throughout normal 
zebrafish embryogenesis using real-time PCR.  We then assessed the dynamics of 
paraoxon-mediated AChE inhibition as a function of concentration, developmental stage, 
and exposure duration (including the potential for recovery), as well as the effects of 
paraoxon on the morphology of secondary motoneuron axons at 96 hpf.  Finally, using a 
locomotor behavior assay with 26-hpf embryos, we quantified the potential effects of 
paraoxon on the frequency of spontaneous tail contractions. 
 
2.2 MATERIALS AND METHODS 
2.2.1 ANIMALS 
Adult wild-type (5D) zebrafish were raised and maintained on a 14-h:10-h 





containing photoperiod enclosures and conditioned reverse osmosis (RO) water (~27-
28°C).  Adult females and males were bred off- or on-system using breeding traps 
suspended within 1- or 3-l tanks, respectively, to allow spawned eggs to settle to the tank 
bottom.  For all experiments described below, newly fertilized eggs were staged 
according to previously described methods (Kimmel et al., 1995). All fish were handled 
and treated in accordance with approved Institutional Animal Care and Use Committee 
(IACUC) protocols at the University of South Carolina – Columbia.   
 
2.2.2 TOTAL RNA ISOLATION AND REAL-TIME PCR 
Three replicate pools of 12- to 98-hpf zebrafish (50 individuals per pool; nine 
total developmental stages) were snap-frozen in liquid nitrogen and stored at -80°C.  
Following homogenization of embryos using sterile blue polypropylene pestles, a SV 
Total RNA Isolation System (Promega) was used to extract total RNA from pooled 
embryo extracts per manufacturer’s instructions.  Prior to sample elution, total RNA 
samples were on-column-digested with DNase-I to remove any DNA contamination.  
Total RNA concentrations and 260/280 ratios were determined using a NanoDrop ND-
2000 spectrophotometer and samples were stored at -80°C.   
Per manufacturer’s instructions, first-strand cDNAs were generated from total 
RNA samples using oligo(dT)15 primers and AMV Reverse Transcriptase (Promega); all 
cDNA samples were stored at -20°C until use.  ache and 18s rRNA cDNAs within each 
developmental stage were amplified using the following primers: ache (185-bp 
fragment), forward primer 5’-CACAGAGCCAATGAAGGTGCACAA-3’, reverse 





forward primer, 5’-TCGCTAGTTGGCATCGTTTATG-3’, reverse primer 5’-
CGGAGGTTCGAAGACGATCA-3’.  As 18s rRNA is stably expressed throughout 
zebrafish embryogenesis (McCurley and Callard, 2008), this gene was selected as an 
internal control for each developmental stage.  Per manufacturer’s instructions, 
approximately 150 ng of ache and 18s rRNA cDNA were PCR-amplified using GoTaq® 
qPCR Master Mix (Promega) and an Applied Biosystems 7900HT Fast Real-Time PCR 
System.  Real-time PCR reaction conditions were: 2 min at 95°C followed by 45 cycles 
of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec.   
Relative quantitation of gene expression within each reaction was calculated using 
the comparative cycle threshold (Ct) method.  For each sample, the threshold cycle for 
reference (18s rRNA) amplification (Ct, 18s rRNA) was subtracted from the threshold cycle 
for target amplification (Ct, ache) to yield a ∆Ct.  The Ct represents the cycle number at 
which the fluorescence signal is significantly above the baseline.  The mean and standard 
deviation of ∆Ct were then calculated for each developmental stage, and the mean ∆Ct for 
12 hpf was subtracted from the mean ∆Ct for each of the remaining developmental stages 
to yield a mean ∆∆Ct.  For each developmental stage, a mean fold change relative to 12 
hpf was calculated using 2-∆∆Ct, and a standard deviation of the mean fold change was 
calculated using 1/(2-∆Ct(σ)) in order to (1) assess the true variance (rather than 12-hpf-
normalized variance) of the mean ∆Ct and (2) ensure that 2-∆Ct(σ) values between zero and 








2.2.3 DEVELOPMENTAL PARAOXON EXPOSURES 
Paraoxon-ethyl (100% purity) was purchased from AccuStandard, Inc. Stock 
solutions of paraoxon were prepared by dissolving chemicals in HPLC-grade acetone; all 
stock solutions were stored at -20°C.  For each experiment, working solutions were 
freshly prepared by spiking stock solutions into embryo media (EM) (5 mM NaCl, 0.17 
mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), resulting in 0.1% acetone within all vehicle 
controls and treatment groups. 
Glass beakers (50-mL capacity) were used for all exposures and, prior to each 
experiment, thoroughly rinsed with solvent (acetone) and RO water.  Immediately 
following spawning, newly fertilized eggs were collected and placed in groups of 
approximately 50 per petri dish within a light- and temperature-controlled incubator until 
5 hpf.  Viable 5D embryos (40 per treatment replicate) were exposed under static 
conditions to vehicle (0.1% acetone) or water-borne paraoxon (31.2 to 500 nM) within 
triplicate glass beakers and incubated at 28°C under a 14-h:10-h light:dark cycle.  At 96 
hpf, all surviving larvae were euthanized with an overdose of tricaine methanesulfonate 
(MS-222, 200-300 mg/L) and evaluated under transmitted light for the following 
developmental abnormalities: decreased body length, craniofacial malformations, trunk 
curvature, tail malformations, pericardial edema, and yolk sac edema.  For AChE assays, 
three replicate pools of 96-hpf larvae (eight individuals per pool; one pool per replicate 
beaker) were transferred to 1.5-ml microcentrifuge tubes and, following aspiration of 
EM, samples were stored at -20°C until assay initiation.  For in situ imaging assessments 





paraformaldehyde/phosphate-buffered saline (PBS) at 4°C and then stored in 1X PBS at 
4°C until imaging.    
To quantify AChE activity over time, embryos were exposed as above to vehicle 
(0.1% acetone) or 500 nM paraoxon from 5 to 96 hpf, euthanized at 24, 48, 72, and 96 
hpf, and stored as described above.  To identify potential recovery of AChE activity after 
exposure to paraoxon, embryos were exposed as above to vehicle (0.1% acetone) or 500 
nM paraoxon during each of the following developmental windows: gastrula and 
segmentation (5-24 hpf); pharyngula (24-48 hpf); hatching (48-72 hpf); or early larval 
(72-96 hpf).  If exposed prior to 72 hpf, embryos were rinsed several times and 
transferred to clean EM until 96 hpf.  At 96 hpf, all larvae were euthanized and stored as 
described above.  
 
2.2.4 ACETYLCHOLINESTERASE ASSAYS USING WHOLE EMBRYO OR LARVAL 
HOMOGENATES 
A microassay method for determination of AChE activity within whole zebrafish 
embryo or larval homogenates was adapted from a previously published endpoint-based 
protocol for mammalian and avian tissue homogenates (Correll and Ehrich, 1991).  For 
each treatment group, three replicate pools of embryos or larvae (eight individuals per 
pool; one pool per replicate beaker) were homogenized in 200 µl of cold 0.1 M phosphate 
buffer using a PowerGen Model 35 Handheld Homogenizer (Fisher Scientific) and 
immediately placed on ice.  Prior to homogenizing each sample, the homogenizer was 
rinsed twice in RO water, and water was wicked away from the homogenizer using a 





50 µL of 0.01 M dithiobisnitrobenzoic acid (DTNB) solution was added to a clean 1.5-ml 
microcentrifuge tube.  For each reagent blank (3 total), 50 µL of phosphate buffer was 
added to each tube containing phosphate buffer and DTNB solution.  For each sample, 50 
µL of embryo or larval homogenate was added to each tube containing phosphate buffer 
and DTNB solution.  After mixing blanks or samples by pipetting several times, 50 µL of 
0.075 M acetylthiocholine iodide was added to each blank or sample tube and mixed 
again by pipetting several times.  The final concentrations of DTNB and 
acetylthiocholine iodide were 0.003 M and 0.019 M, respectively.  All blanks and 
samples were immediately transferred to a clear 96-well microplate and initial 
absorbance at 490 nm was measured using a Perkin Elmer Victor X3.  Although 
absorbance for this assay has historically been measured between 405 to 412 nm 
(Adewusi and Steenkamp, 2011; Ellman et al., 1961), we found that readings at 490 nm 
provided better separation of blank and control sample absorbance readings.  The plate 
was incubated at 37oC for 30 min, and absorbance was measured again at 490 nm after 
the wells were mixed by pipetting several times.  An incubation time of 30 min was 
selected for the AChE microassay, as this duration yielded (1) maximum absorbance 
within control embryo or larval homogenates; (2) non-detectable absorbance within 
reagent blank samples; and (3) as a result, maximum assay sensitivity and potential for 
detection of paraoxon-mediated AChE inhibition.  
To quantify total protein within each homogenate, 300 µL of Coomassie Plus 
Bradford Assay Reagent (ThermoScientific) was added to the appropriate number of 
wells within a clear 96-well microplate, and 10 µL of 0.1 M phosphate buffer (blank), 





µg/mL) prepared in 0.1 M phosphate buffer was then added to wells containing assay 
reagent.  After mixing contents of the wells by pipetting up and down several times, the 
plate was incubated for 10 min and absorbance of BSA standards and samples was 
measured using a Perkin Elmer Victor X3 Microplate Reader. 
For the first and second readings, average blank absorbance was subtracted from 
the sample absorbance to account for non-enzymatic hydrolysis of substrate. The rate of 
change was calculated for each sample using the following equation (Correll and Ehrich, 
1991; Ellman et al., 1961): Rate (moles/L per min) = ((Abst1 – Abst0 / 30 min) / 
1.36X104).  The estimated rate of change was then normalized to total protein using the 
following equation: Rate (moles/L per min per mg) = (Change in Abs. / 1.36X104) / mg 
protein.  Percent decrease (or inhibition) of AChE activity was calculated relative to 
vehicle controls. 
 
2.2.5 IN SITU IMAGING ASSESSMENTS OF SECONDARY MOTONEURONS WITHIN 96-HPF 
LARVAE 
To remove pigmentation and enhance fluorescence imaging in vivo, fixed 96-hpf 
larvae (four individuals per treatment) were incubated for 30 min at room temperature in 
fresh 3% H2O2/0.5% KOH and then washed in PBS for 5 min to stop the bleaching 
reaction.  To allow adequate antibody penetration within all tissues, bleached 
(transparent) larvae were permeabilized by incubating in cold acetone at -20°C for 30 
min and then rinsing four times in PBS/0.1% Tween-20 (PBST) for 5 min per wash.  
Permeabilized larvae were incubated in fresh blocking buffer (PBST/2% sheep serum/2 





incubated overnight at 4°C with gentle agitation in blocking buffer containing a 1:20 
dilution of zn-8 IgG1 supernatant.  zn-8 IgG1 is a zebrafish-specific antibody that 
recognizes neuronal cell surface markers within the central and peripheral nervous 
system of developing zebrafish (Trevarrow et al., 1990).  Following incubation in 
primary antibodies, larvae were washed five times with gentle agitation in PBST at room 
temperature for 15 min each.  Larvae were then incubated overnight at 4°C with gentle 
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)-
conjugated goat anti-mouse IgG1 (Invitrogen) to visualize zn-8 localization in situ.  
Finally, secondary antibody-labeled larvae were washed five times with gentle agitation 
in PBST at room temperature for 15 min each, and then stored in PBS at 4°C until 
imaging. 
The zn-8-labeled larvae were mounted within 80% glycerol on a standard 
microscope slide and imaged using an Olympus FluoView FVX IX70 laser-scanning 
confocal microscope.  For imaging the trunk, fish were oriented in right lateral 
recumbency and focused under transmitted light using a 10X objective.  An XYZ optical 
sectioning mode was used to image AF488 fluorescence within segments 7, 8, and 9 of 
each larval trunk using a total of 12 sagittal confocal sections at a 5-µm Z-step interval.  
Based on our preliminary data, 12 confocal sections and a 5-µm Z-step interval provided 
complete coverage of secondary motoneurons within 96-hpf larvae.  Following 
acquisition at different depths, composite Z-stack images for each individual were 
generated to provide a final merged image for quantitative analysis within Olympus’ 
FluoView software.  The following endpoints were assessed to determine whether 





presence or absence of ventral, medial, and dorsal motoneuron axons; 2) length of 
ventral, medial, and dorsal motoneuron axons; and 3) presence of motoneuron axonal 
pathfinding errors.  
 
2.2.6 QUANTIFICATION OF SPONTANEOUS TAIL CONTRACTIONS WITHIN 26-HPF EMBRYOS 
When reared at 28.5°C, spontaneous tail contractions within dechorionated 
zebrafish embryos first appear at 17 hpf, with a peak frequency at 19 hpf and gradual 
decrease by 27 hpf (Saint-Amant and Drapeau, 1998).  When chorionated 5D embryos 
are reared at 28°C (based on our own preliminary data), spontaneous tail contractions are 
delayed, resulting in a peak frequency at 26 hpf.  Therefore, we evaluated locomotor 
behavior at 26 hpf within chorionated embryos to maximize assay sensitivity and 
eliminate potential confounding effects due to pronase treatment and embryo handling.  
Viable 5D embryos (40 per treatment replicate) were exposed to vehicle (0.1% acetone) 
or water-borne paraoxon (31.2 to 500 nM) within triplicate glass beakers and incubated at 
28°C under a 14-h:10-h light:dark cycle until 25 hpf.  All embryos remained within the 
glass beakers containing the treatment solution and were allowed to acclimate to room 
temperature for one hour prior to imaging.  At 26 hpf, all embryos within each treatment 
beaker were continuously videoed once for 25 s under transmitted light using an 
Olympus MVX10 MacroView stereomicroscope equipped with an Olympus DP72 
Digital Color Camera and Olympus DP2-BSW Imaging Software.  The number of tail 
flips per 25 s was then counted for each surviving and non-malformed embryo within 
each treatment.  Any surviving embryos containing tail malformations were not counted 





locomotion compared to the vehicle control embryos.  
 
2.2.7 STATISTICAL ANALYSES 
All statistical procedures were performed using SPSS Statistics 19.0.  A general 
linear model (GLM) analysis of variance (ANOVA) (α = 0.05) was used for all real-time 
PCR, AChE activity, axon length, and behavioral assay data, as these data did not meet 
the equal variance assumption for non-GLM-based ANOVAs. Pair-wise Tukey-based 
multiple comparisons of least square means were performed to identify significant stage- 
or treatment-related effects. 
 
2.3 RESULTS 
2.3.1 ACHE TRANSCRIPTS RAPIDLY INCREASE FOLLOWING SEGMENTATION 
To assess ache expression during zebrafish embryogenesis, we extracted total 
RNA from nine different developmental stages (12 to 98 hpf) and, following cDNA 
synthesis, PCR-amplified a 185-bp ache fragment from each stage using real-time PCR.  
Relative to 12 hpf, there was a rapid stage-dependent increase in ache transcript levels 
from early-pharyngula (26 hpf) through the end of the early larval period (98 hpf) (Figure 
2.1).  Although levels were not significantly higher within pharyngula-stage embryos, 
ache expression was, on average, approximately 25- and 60-fold higher during hatching 
and early larval periods, respectively, relative to 12 hpf (Figure 2.1).  Even though ache 
expression was detected during segmentation, these data suggest that ache transcription is 







2.3.2 PARAOXON-INDUCED ACHE INHIBITION IS DEPENDENT ON DEVELOPMENTAL STAGE 
AND CONCENTRATION 
To address the potential interaction of developmental stage and paraoxon 
concentration on AChE activity, we exposed developing zebrafish embryos to paraoxon 
from 5 to 96 hpf and used a modified Ellman assay to determine the rate of AChE 
activity within homogenates from whole embryos or larvae.  Based on these experiments, 
we found a stage-dependent increase in AChE activity in vehicle controls but not 500-nM 
paraoxon treatments (Figure 2.2A).  In addition, there were significant within-stage 
differences in AChE activity between vehicle control and 500 nM paraoxon treatments at 
72 and 96 hpf but not 24 or 48 hpf (Figure 2.2A).  When embryos were exposed to 
increasing concentrations of paraoxon (31.2 to 500 nM), AChE activity within 96-hpf 
larvae decreased in a concentration-dependent manner, with significant AChE inhibition 
first detected at 62.5 nM paraoxon (Figure 2.2B).  At the highest paraoxon concentration 
tested (500 nM), AChE activity was decreased by approximately 85% compared to 
vehicle controls (Figure 2.2B), demonstrating that exposure of developing zebrafish 
embryos to 500 nM paraoxon nearly eliminated the ability of AChE to hydrolyze 
acetylcholine (ACh) within 96-hpf larvae.  
 
2.3.3 PARAOXON-INDUCED ACHE ACTIVITY RECOVERS FOLLOWING TRANSFER TO CLEAN 
WATER 
To determine whether the effects of paraoxon on AChE activity were reversible, 





windows and allowed to recover in clean water until 96 hpf.  Similar to results presented 
in Figure 2.2A, AChE activity increased as a function of developmental stage within 
vehicle control embryos (Figure 2.3).  However, AChE activity within embryos exposed 
to 500 nM paraoxon from 24 to 48 hpf was inhibited by 76% and 29% at 48 and 72 hpf, 
respectively, but returned to levels similar to vehicle controls by 96 hpf (Figure 2.3).  
Likewise, AChE activity within embryos exposed to 500 nM paraoxon from 48 to 72 hpf 
was inhibited by 89% and 35% at 72 and 96 hpf, respectively (Figure 2.3).  However, the 
recovery duration (24 h) within this treatment group was insufficient for AChE activity to 
fully recover when embryos were transferred into clean water.  Overall, we found that 
paraoxon-induced effects on AChE activity were reversible, with full recovery in AChE 
activity by 48 h after transferring to clean water (Figure 2.3). 
 
2.3.4 PARAOXON DOES NOT AFFECT SECONDARY MOTONEURON AXON MORPHOLOGY 
As exposure to 500 nM paraoxon resulted in trunk malformations and decreased 
body length, we focused our imaging analyses on 96-hpf larvae exposed to sub-lethal, 
non-teratogenic paraoxon concentrations (≤250 nM) in order to minimize potential 
confounding effects of gross abnormalities on axon morphology. Therefore, we first 
exposed developing zebrafish to increasing, non-teratogenic concentrations of paraoxon 
(31.2 to 250 nM) from 5 to 96 hpf, and then used whole-mount immunohistochemistry 
and confocal microscopy to label and image secondary motoneurons in situ. Normal 
development and survival was >90% within vehicle controls and all paraoxon 
concentrations tested. Relative to vehicle controls, we found no significant differences in 





concentrations tested (Figure 2.4A and 2.4B).  Moreover, we found no significant effects 
on secondary motoneuron axon abundance and pathfinding (data not shown), nor dorsal, 
medial, and ventral axon lengths within paraoxon-exposed larvae compared to vehicle 
controls (Figure 2.4C and 2.4D).  
 
2.3.5 PARAOXON INCREASES THE FREQUENCY OF SPONTANEOUS TAIL CONTRACTIONS 
WITHIN 26-HPF EMBRYOS 
To determine whether paraoxon affected spontaneous locomotor behavior, 
developing embryos were exposed to paraoxon (31.2 to 500 nM) from 5 to 26 hpf and the 
frequency of spontaneous tail contractions was assessed at 26 hpf. Normal development 
and survival was >95% within vehicle controls and all paraoxon concentrations tested. As 
no significant differences among within-treatment replicates were detected (p>0.05), all 
individuals within each treatment were combined for statistic analysis. Compared to 
vehicle controls, we observed a significant increase in the frequency of spontaneous tail 
contractions following exposure to paraoxon concentrations as low as 31.2 nM (the 
lowest concentration tested) (Figure 2.5). 
 
2.4 DISCUSSION 
  Using paraoxon as a reference AChE inhibitor, the objective of this study was to 
develop an AOP that provided quantitative linkages across levels of biological 
organization during zebrafish embryogenesis. Within normal embryos, we first 
demonstrated that ache transcripts and AChE activity rapidly increased in a stage-





embryos to paraoxon from 5 to 96 hpf resulted in significant stage- and concentration-
dependent AChE inhibition, albeit AChE activity returned to vehicle control levels within 
48 h following transfer to clean water.  Even in the presence of significantly decreased 
AChE activity, exposure to non-teratogenic paraoxon concentrations (≤250 nM) did not 
lead to adverse effects on secondary motoneuron axon morphology nor obvious effects 
on larval swimming behavior at 96 hpf based on preliminary observations under 
transmitted light (data not shown).  Therefore, we investigated the potential effects of 
paraoxon exposure on locomotor behavior at 26 hpf (rather than larval swimming 
behavior), and found that exposure to paraoxon concentrations as low as 31.2 nM (the 
lowest concentration tested) significantly increased the frequency of spontaneous tail 
contractions compared to vehicle controls.  Importantly, this paraoxon-induced effect on 
spontaneous behavior occurred at an early embryonic stage when minimal AChE 
expression and activity was present relative to hatching- and early larval-stage embryos.   
Based on real-time PCR, we found that ache expression within normal embryos 
was detected during somitogenesis and rapidly increased following segmentation through 
completion of the early larval period.  Although we did not localize ache expression 
within developing embryos, our real-time PCR data suggest that the rapid increase in 
ache expression coincided with the onset of secondary neurogenesis.  Based on whole-
mount in situ hybridization, previous studies have demonstrated that ache transcripts first 
appear within primary motoneurons of the rostral spinal cord between 12 to 14 hpf and, 
by the end of segmentation, are localized within primary neurons – including sensory 
neurons, reticulospinal interneurons, and primary motoneurons – of the entire spinal cord 





expression is detected within developing axons, the majority of ache transcripts are 
localized to cell bodies of primary and secondary neurons during early zebrafish 
embryogenesis (Bertrand et al., 2001).  While ache mRNA localization has, to our 
knowledge, not been assessed beyond 27 hpf, we suspect that high levels of ache 
expression during hatching- and early larval-stage zebrafish embryos are associated with 
a dense population of secondary neuron cell bodies within the trunk and cranial regions. 
Within control embryos, we observed a stage-dependent increase in AChE 
activity that coincided with the timing of increased ache expression. However, exposure 
to 500 nM paraxon from 5 to 96 hpf resulted in near elimination of AChE activity (>80% 
inhibition) at 72 and 96 hpf, a finding that is consistent with previous studies reporting a 
40% and 98% decrease in AChE activity following exposure to approximately 400 and 
800 nM paraoxon, respectively, from 0.5 to 48 hpf (Kuster, 2005; Kuster and 
Altenburger, 2006). Likewise, exposure of zebrafish embryos to 300 nM chlorpyrifos 
from 6 to 96 hpf resulted in an 81% decrease in AChE activity by 96 hpf (Yen et al., 
2011), and exposure to 300 nM chlorpyrifos-oxon (the neurotoxic metabolite of 
chlorpyrifos) from 24 to 72 hpf resulted in an 88% decrease in AChE activity by 72 hpf 
(Yang et al., 2011). Our results also demonstrated that, similar to previous studies using 
other AChE inhibitors within different experimental systems (Arduini et al., 2007; Jiang 
et al., 2012), paraoxon-induced effects on AChE inhibition were fully reversible within 
48 h of being transferred to clean water.  Moreover, the timing of paraoxon exposure 
during zebrafish embryogenesis did not impact the magnitude of recovery, demonstrating 
that all developmental windows tested were equally susceptible to paraoxon-mediated 





data suggest that reversible effects on AChE inhibition following transfer to clean water 
may be a result of (1) paraoxon metabolism and elimination (and ultimately dissociation 
of paraoxon from AChE), (2) rapid degradation of inhibited AChE, and/or (3) increased 
production of non-inhibited AChE – and, as a result, dilution of inhibited AChE – during 
later stages of embryogenesis.  Regardless of the mechanism of recovery, our results 
suggest that transient, short-term exposures to paraoxon during zebrafish embryogenesis 
do not lead to persistent effects on AChE activity. 
Although we observed a significant concentration-dependent decrease in AChE 
activity within 96-hpf larvae, exposure from 5 to 96 hpf to all paraoxon concentrations 
tested (31.2 to 250 nM) resulted in no significant impacts on embryonic development and 
secondary motoneuron axon morphology, findings that are consistent with previous 
studies demonstrating that <80% AChE inhibition does not result in abnormal 
development of 48-hpf zebrafish embryos (Kuster, 2005; Kuster and Altenburger, 2006). 
However, contrary to our results with paraoxon, non-teratogenic concentrations of 
chlorpyrifos-oxon (100 nM) significantly inhibited axonal growth of primary and 
secondary motoneurons, as well as Rohon-Beard and dorsal root ganglia sensory neurons, 
within developing zebrafish embryos (Jacobson et al., 2010; Yang et al., 2011), an effect 
that was hypothesized to be mediated via disruption of the morphogenic activity of AChE 
(Yang et al., 2011).  As such, although both are potent AChE inhibitors at similar 
nominal exposure concentrations, paraoxon and chlorpyrifos-oxon appear to exhibit 
distinct downstream effects on secondary neurogenesis, a discrepancy that is consistent 
with the long-standing conclusion that, while sharing a common target (AChE), all OP 





investigations were focused on secondary motoneurons, our findings are also consistent 
with previous studies that have reported no effects on primary neurogenesis following 
deletion of the catalytic and/or neuritogenic carboxy-terminal domains of AChE within 
zebrafish (Behra et al., 2002; Downes and Granato, 2004). Therefore, compared to data 
generated using ache mutant lines, our data with paraoxon support the conclusion that 
catalytic AChE function is dispensable for motoneuron development with zebrafish 
embryos.  
As exposure to non-teratogenic paraoxon concentrations did not impact larval 
swimming behavior at 96 hpf based on preliminary observations under transmitted light, 
we evaluated the potential effects of paraoxon exposure on spontaneous tail contractions 
at 26 hpf – an early locomotor behavior that (1) results from innervation of primary (not 
secondary) motoneuron axons to target axial muscles (Myers et al., 1986; Westerfield et 
al., 1986) and (2) occurs in the absence of cues such as touch (Brustein et al., 2003; 
Kimmel et al., 1972; Saint-Amant and Drapeau, 1998). Even in the presence of minimal 
AChE activity, the frequency of spontaneous tail contractions was significantly higher 
within 26-hpf embryos exposed to all paraoxon concentrations tested (31.2 to 500 nM). 
Therefore, this adverse outcome (spontaneous behavior) was sensitive to paraoxon 
exposure in the absence of significant AChE expression and activity and, as such, may be 
mediated via paraoxon-induced activation of ACh receptors (AChRs) and/or disruption of 
non-cholinergic signaling (Figure 2.6).  
Although nicotinic and muscarinic AChRs are present within primary 
motorneuron axons during early zebrafish embryogenesis (Behra et al., 2002), high 





behavior within dechorionated 28-hpf embryos (Thomas et al., 2009), suggesting that 
endogenous ACh concentrations are likely too low for sustained AChR activation and 
production of motor output. However, exposure to micromolar nicotine concentrations 
increases the frequency of spontaneous tail contractions at 28 hpf (Thomas et al., 2009), 
demonstrating that, at minimum, nicotinic AChRs are functional at this stage. Similar to 
nicotine, paraoxon-induced effects on spontaneous tail contractions may, in part, be 
mediated through direct activation of AChRs since (1) our data show that AChE activity 
is virtually absent at this stage and (2) previous studies have demonstrated that paraoxon 
competitively inhibits agonist binding to electric ray (Torpedo sp.) nicotinic AChR, albeit 
the effective concentration was two orders of magnitude higher than the concentration 
required to inhibit 50% of AChE activity (Katz et al., 1997).  
On the other hand, Drapeau and colleagues have suggested that spontaneous 
locomotion within embryonic zebrafish is regulated by electrical coupling-type 
mechanisms rather than classical mechanisms of chemical neurotransmission since 
spontaneous contractions were inhibited by gap junction blockers but were not affected 
by glycine and glutamate receptor antagonists nor botulinum toxin (a broad-spectrum 
inhibitor of synaptic transmission) (Brustein et al., 2003; Saint-Amant and Drapeau, 
2000, 2001).  Prior to formation and maturation of chemical synapses, gap junctions play 
a critical role in linking spinal cord neurons and propagating spontaneous, electrical 
current-driven depolarization within the motor network (Saint-Amant and Drapeau, 
2001).  Therefore, in addition to direct AChR activation, paraoxon-induced effects on 
spontaneous behavior within zebrafish embryos may be due to abnormal development 





independent of classical cholinergic signaling.  
In summary, our data suggest that (1) normal AChE activity is not required for 
secondary motoneuron development and (2) AChE inhibition may not be associated with 
an increased frequency of spontaneous tail contractions at 26 hpf following paraoxon 
exposure. Although paraoxon was a potent AChE inhibitor within zebrafish embryos, this 
initiating event was not linked to adverse outcomes on secondary motoneuron 
development at 96 hpf and was fully reversible within 48 h following transfer of embryos 
to clean water.  Moreover, the most sensitive paraoxon-induced adverse outcome in this 
study – an increased frequency of spontaneous tail contractions at 26 hpf – occurred in 
the absence of significant AChE activity.  While it’s unclear whether paraoxon-induced 
effects on spontaneous behavior are mediated through direct AChR activation and/or 
effects on non-cholinergic signaling, this adverse outcome at 26 hpf did not lead to 
adverse impacts on secondary motoneuron development and larval swimming behavior 
later in development (96 hpf), suggesting that primary neurogenesis is more sensitive to 
paraoxon exposure than secondary neurogenesis. In addition, increased tail flip behavior 
may be indicative of hyperactivity, a common neurological effect associated with OP 
insecticides, and may result in an increase in energy expenditure. As such, while we 
agree that AOPs are useful frameworks for facilitating development of chemical 
screening and prioritization strategies, this case study using a potent reference chemical 
highlights the potential challenges in developing AOPs that provide quantitative linkages 







Figure 1.1: ache transcripts rapidly increase following segmentation. 
 
Figure 2.1: ache transcripts rapidly increase following segmentation.  Relative to 12 hpf, 
a significant increase in ache expression was detected beginning at 50 hpf.  Fold change 
data are mean ± standard deviation relative to 12 hpf.  An asterisk denotes a significant 






Figure 2: Paraoxon-induced AChE inhibition is dependent on developmental stage and concentration 
 
 
Figure 2.2: Paraoxon-induced AChE inhibition is dependent on developmental stage (A) 
and concentration (B).  In Panel A, an asterisk denotes a significant difference relative to 
24 hpf within the same treatment (p<0.05), and a number sign denotes a significant 
difference from vehicle controls within the same stage (p<0.05).  In Panel B, an asterisk 
denotes a significant difference from vehicle controls (p<0.05).  N = three replicate pools 







Figure 2.3: Paraoxon-induced effects on AChE activity are reversible following transfer 
to clean water.  An asterisk denotes a significant difference relative to 24 hpf within the 
same treatment (p<0.05), whereas a number sign denotes a significant difference from 
vehicle controls within the same stage (p<0.05).  N = three replicate pools of eight 96-hpf 
larvae per pool. 
  





Figure 4: Paraoxon does not affect secondary motoneuron axon morphology 
 
 
Figure 2.4: Paraoxon does not affect secondary motoneuron axon morphology.  Panels A 
and B show the gross morphology of 96-hpf larvae following exposure to vehicle (0.1% 
acetone) or the highest non-teratogenic paraoxon concentration tested (250 nM), 
respectively. Panel C shows a representative confocal Z-stack image of secondary 
motoneurons within the trunk of a vehicle-treated 96-hpf fish (dorsal, medial, and ventral 
axons are labeled). Panel D shows axon length data for secondary motoneurons within 
96-hpf larvae following exposure to vehicle (0.1% acetone) or paraoxon (31.2 to 250 
nM). N = three segments per individual and four larvae per treatment.  No significant 










Figure 2.5: Paraoxon increases the frequency of spontaneous tail contractions within 26-
hpf embryos. Box plots show the 25th, 50th, and 75th percentile for each treatment tested, 
and error bars below and above the box represent the 10th and 90th percentile, 
respectively.  Filled circles represent data points less than or greater than the 10th or 90th 
percentile, respectively.  Treatments that do not share the same letter are significantly 
different (p<0.05) from each other. All individuals within each treatment were combined 
for statistic analysis since no significant differences among within-treatment replicates 
were detected (p>0.05).  Therefore, sample sizes reflect the total number of embryos 











Figure 2.6: Proposed AOP for paraoxon exposure during early zebrafish embryogenesis 
(5 to 26 hpf). Dotted line denotes a minor contribution to the AOP since spontaneous 








HIGH-CONTENT SCREENING ASSAY FOR IDENTIFICATION OF CHEMICALS IMPACTING 
 CARDIOVASCULAR FUNCTION IN ZEBRAFISH EMBRYOS 
3.1 INTRODUCTION 
High-content screening (HCS) assays using zebrafish have been developed to 
evaluate locomotion (Ingebretson and Masino, 2013; Mirat et al., 2013); nanoparticle and 
chemical exposures (Lin et al., 2013; Padilla et al., 2012); bacterial infections (Veneman 
et al., 2013); energy expenditure (Renquist et al., 2013); and drug-induced heart 
malformations and impacts on cardiac function (Burns et al., 2005; Spomer et al., 2012; 
Tran et al., 2007; Wen et al., 2012). Despite significant advancements, targeted HCS 
assays using zebrafish are still needed to better evaluate chemical effects on 
organogenesis and begin classifying chemicals by toxicologically relevant MOAs. 
Therefore, the objective of this study was to develop a 384-well-based HCS assay with 
sufficient power, replication, and exposure concentrations to screen and identify 
chemicals that affect cardiovascular function at sub-lethal, non-teratogenic 
concentrations.   
 
3.2 MATERIALS AND METHODS 
3.2.1 ANIMALS 
For all assays described below, we relied on a robust line of transgenic zebrafish 





endothelial cells (Lawson and Weinstein, 2002). Adult fli1:egfp zebrafish were 
maintained on a 14-h:10-h light:dark cycle within a Mini Mass Embryo Production 
System (mini-MEPS) (Aquatic Habitats, Inc., Apopka, FL) containing a photoperiod light 
cycle dome and recirculating conditioned reverse osmosis (RO) water (~27-28°C).  Adult 
females and males were bred directly within the mini-MEPS, or bred off-system within a 
light- and temperature-controlled incubator using breeding traps suspended within 1-L 
tanks.  For all experiments described below, newly fertilized eggs were staged according 
to previously described methods (Kimmel et al., 1995). All fish were handled and treated 
in accordance with approved Institutional Animal Care and Use Committee (IACUC) 
protocols at the University of South Carolina – Columbia, South Carolina.   
 
3.2.2 CHEMICALS 
Chemicals were purchased from ChemService, Inc. (West Chester, PA), Tocris 
Bioscience (Bristol, UK), and Cambridge Isotope Laboratories, Inc. (Andover, MA); 
chemical names, chemical formulas, CAS registry numbers, and purities are provided 
within Table A.1.  Stock solutions of each chemical were prepared by dissolving 
chemicals in HPLC-grade dimethyl sulfoxide (DMSO), and then performing two-fold 
serial dilutions into DMSO to create stock solutions for each working solution.  All stock 
solutions were stored at room temperature within 2-mL amber glass vials containing 
polytetrafluoroethylene (PTFE)-lined caps.  For each assay, working solutions of tricaine 
methanesulfonate (MS-222) (Western Chemical, Inc., Ferndale, WA) were freshly 
prepared by dissolving MS-222 into embryo media (EM) (5 mM NaCl, 0.17 mM KCl, 





prepared by spiking stock solutions into EM, resulting in 0.1% DMSO within all vehicle 
control and treatment groups.   
 
3.2.3 HIGH-CONTENT SCREENING (HCS) ASSAY  
EXPOSURE SETUP. Black 384-well microplates containing 0.17-mm glass-bottom 
wells (Matrical Bioscience, Spokane, WA) were used for all HCS assays. Immediately 
following spawning, newly fertilized eggs were collected and placed in groups of 
approximately 50 per glass petri dish within a light- and temperature-controlled incubator 
until 5 hours post-fertilization (hpf).  For each HCS assay, 384 viable fli1:egfp embryos 
were arrayed at 5 hpf into a 384-well plate (one embryo per well) containing 50 µL per 
well of vehicle (0.1% DMSO) or treatment solution, and then incubated at 28°C under a 
14-h:10-h light:dark cycle and static conditions until 72 hpf. 
IMAGE ACQUISITION. At 72 hpf, the plate was removed from the incubator, and 
zebrafish embryos were anesthetized with 100 mg/L MS-222 by adding 25 µL of 300 
mg/L MS-222 to 50 µL of vehicle or treatment solution.  The plate was then centrifuged 
at 200 rpm for 2 minutes to help orient hatched embryos into right or left lateral 
recumbency.  Using automated image acquisition protocols and parameters (Yozzo et al., 
2013b) optimized for our ImageXpress® Micro (IXM) Widefield High-Content Screening 
System (Molecular Devices, Sunnyvale, CA), each embryo was imaged to analyze the 
following endpoints: heart rate; circulation; pericardial area; body length; and 
intersegmental vessel area (Figure 3.1). During the entire image acquisition period, 
internal temperature within the IXM system was maintained between 25-27°C by 





through the IXM with a portable fan; internal temperature was monitored and recorded at 
initiation and termination of each imaging protocol using a digital thermometer.  In 
accordance with National Institutes of Health (NIH) guidelines (National Institutes of 
Health), 72-hpf embryos were then euthanized by placing the plate at 4°C for 30 minutes. 
DATA EXTRACTION. Custom journal scripts for extraction of heart rate, 
circulation, pericardial area, body length, and intersegmental vessel area data were 
developed using MetaXpress® 4.0.0.24 software (Molecular Devices, Sunnyvale, CA).  
Prior to data extraction, stream acquisitions within each well were inspected within 
MetaXpress to assess embryo orientation and survival. Coagulated embryos or developed 
embryos lacking a heartbeat were considered dead. Using these survival criteria, only 
hatched and alive embryos positioned in right or left lateral recumbency were analyzed.  
Interactive semi-automated journal scripts were used to isolate regions of interest and 
quantify heart rate, circulation, pericardial area, and intersegmental vessel area, whereas a 
fully automated journal script was used to quantify body length.  Examples of raw and 
analyzed images of control zebrafish for each endpoint are provided in Figure 3.2.  
Additional details of the data extraction and analysis process are provided in Yozzo et al. 
(2013b). 
 
3.2.4 STATISTICAL ANALYSES 
All statistical procedures were performed using SPSS Statistics 19.0 (Chicago, 
IL).  A general linear model (GLM) analysis of variance (ANOVA) (α = 0.05) was used 





ANOVAs. Pair-wise Tukey-based multiple comparisons of least square means were 
performed to identify significant treatment-related effects. 
 
3.3 RESULTS 
3.3.1 OPTIMIZATION OF MS-222-BASED ANESTHESIA 
 As high MS-222 concentrations are known to adversely impact cardiac function 
within zebrafish embryos (Burns et al., 2005), we first determined the lowest MS-222 
concentration that fully anesthetized hatched 72-hpf embryos in the absence of significant 
effects on heart rate. We exposed 72-hpf zebrafish to 50-300 mg/L MS-222 for 30 
minutes, and then acquired and analyzed images for heart rate as described in Figure 3.1.  
As 50 mg/L MS-222 was insufficient to fully anesthetize hatched 72-hpf embryos, MS-
222-induced effects on heart rate were only analyzed within 100-300 mg/L MS-222 
treatment groups.  Although percent survival was similar across all MS-222 
concentrations (82-96%), there was a concentration-dependent decrease in sample size 
(Figure 3.3A) and percent of successfully imaged embryos used for analysis of heart rate 
(Table 3.1) – an effect that was largely a result of a concentration-dependent increase in 
the percentage of embryos with orientation in dorsal recumbency.   
While mean heart rates were significantly different across all concentrations 
tested (Figure 3.3A), these minor differences were a result of high sample sizes, minimal 
variation, and, as a result, high statistical power.  Although mean heart rates across all 
MS-222 concentrations tested were similar to heart rates of non-anesthetized 72-hpf 
zebrafish analyzed at 28°C (Burns et al., 2005), we selected 100 mg/L MS-222 for all 





necessary to fully anesthetize hatched 72-hpf embryos and (2) yielded the highest percent 
of successfully imaged embryos (Table 3.1).  Using this MS-222 concentration, we then 
assessed heart rate every 12 minutes over a 132-minute image acquisition period 
(following an initial immersion for 30 minutes), but found no significant effects on heart 
rate across all time-points analyzed (Figure 3.3B).  Therefore, these data demonstrated 
that prolonged immersion of hatched 72-hpf embryos in 100 mg/L MS-222 provided full 
anesthetization and high imaging success rates in the absence of significant effects on 
heart rate over time. 
 
3.3.2 ASSESSMENT OF BACKGROUND VARIABILITY 
  To evaluate background variability, we imaged four control plates containing 
embryos incubated in EM from 5-72 hpf, and then immersed in 100 mg/L MS-222 for 30 
minutes prior to imaging.  Heart rate, circulation, pericardial area, body length, and 
intersegmental vessel area were analyzed for each control plate using the parameters 
described in Yozzo et al. (2013b). Percent survival and image success of hatched 
embryos ranged from 93-99% and 42-74%, respectively (Table 3.2). Although 
intersegmental vessel area and circulation data were variable, body length, pericardial 
area, and heart rates were relatively consistent within and across plates (Figure 3.4).  
Based on these data, we concluded that control performance within this HCS assay was 








3.3.3 CHEMICAL SCREENING 
Using protocols described in Yozzo et al. (2013b), 10 chemicals (Table A.1) were 
screened to evaluate the potential for targeted effects on the cardiovascular system. This 
sub-set of chemicals was selected in order to represent a range of chemical classes and 
mechanisms of action.  Based on a published list of known classes of cardiovascular 
toxicants (Casarett et al., 2008; Kleinstreuer et al., 2011), nicotine, pyridaben, CL-4AS-1, 
17β-estradiol, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and genistein were 
hypothesized to be ‘positive’ within our assay, whereas endosulfan, paraoxon, 
cypermethrin, and imidacloprid were hypothesized to be ‘negative’ within our assay. 
Decision criteria for survival (>70% survival) and body length (<10% decrease relative to 
vehicle controls) were developed based on performance within our control plates (Table 
3.2 and Figure 3.4) as well as existing OECD test guidelines (http://www.oecd-
ilibrary.org/content/package/chem_guide_pkg-en) for fish early life-stage toxicity 
(OECD TG 210) and rodent chronic toxicity (OECD TG 452) to (1) minimize Type I and 
II errors and reliably identify treatment-related effects and (2) focus our analyses on 
targeted impacts on the cardiovascular system in the absence of significant effects on 
embryonic growth (Figure 3.5). Based on the highest chemical concentration meeting 
both criteria, we then performed a cluster analysis using QCanvas 1.2 
(http://compbio.sookmyung.ac.kr/~qcanvas/) (Figure 3.6A). Pyridaben was the most 
potent chemical to affect survival, as 0.78 µM was the highest concentration analyzed 
due to 0% survival at higher concentrations. In addition, TCDD exposure resulted in the 
most potent effects on body length even though survival was >70% at all concentrations 





concentration tested since we were limited by the concentration of DMSO stock solution 
purchased from Cambridge Isotope Laboratories; therefore, exposure to TCDD 
concentrations >0.155 µM would likely have resulted in <70% survival. On the contrary, 
imidacloprid and nicotine were the least potent chemicals and did not affect body length 
nor survival across all concentrations tested (0.05 – 50 µM). 
 To determine targeted effects on the cardiovascular system, heart rate, circulation, 
pericardial area, and intersegmental vessel area were assessed within treatment groups 
with >70% survival and/or <10% decrease in body length relative to vehicle controls.  
Out of 10 chemicals screened, TCDD and paraoxon were the only chemicals to result in a 
significant concentration-dependent effect on one or more endpoints analyzed within 
treatment groups meeting both analysis criteria (Figure 3.6B).  Mean body length was 
>10% lower than vehicle controls for paraoxon and TCDD concentrations higher than 
0.78 and 0.004 µM, respectively. Therefore, these concentrations were the highest 
concentrations analyzed for all endpoints. TCDD significantly decreased (p<0.05) arterial 
circulation at the highest concentration analyzed (0.004 µM), and significantly increased 
(p<0.05) pericardial area at all concentrations analyzed (1.51x10-4-0.004 µM) without 
significantly affecting venous circulation, heart rate, and intersegmental vessel area. On 
the other hand, paraoxon significantly decreased heart rate (p<0.05) at all concentrations 
tested (0.05-50 µM) in the absence of effects on any other endpoints. 
 
3.4 DISCUSSION 
Although previous HCS assays using zebrafish have examined drug-induced heart 





Spomer et al., 2012; Tran et al., 2007; Wen et al., 2012), to our knowledge this is the first 
HCS assay to provide a more comprehensive platform for quantifying body length, heart 
rate, pericardial area, circulation, and intersegmental vessel area within the same embryo 
– an advance that will, in the long-term, decrease the amount of time, zebrafish embryos, 
and high-purity reference material needed for screening and identification of chemicals 
impacting cardiovascular function.  Using 384-well format, we were also able to increase 
sample size (32 per treatment) and examine a broad concentration-response (vehicle 
control and 11 chemical concentrations per plate). While we are not the first to use 384-
well plates, the majority of HCS assays using zebrafish rely on 96-well plates or low 
sample sizes per treatment if using 384-well plates (Padilla et al., 2012; Spomer et al., 
2012; Tran et al., 2007).  To reduce the potential for adverse side effects of anesthetizing 
with MS-222, we attempted to immobilize hatched embryos by pre-exposing to light as 
suggested in Burns et al. (2005); however, these attempts were unsuccessful, precluding 
the possibility of eliminating MS-222-based anesthetization.  Nonetheless, 
anesthetization of embryos using MS-222 did not affect heart rate over time (Figure 3.3), 
and heart rates in this study were similar to heart rates of non-anesthetized, 72-hpf 
zebrafish embryos incubated at the same temperature (Burns et al., 2005).  After analysis 
of control plates demonstrated the assay was reliable, we then screened 10 chemicals and 
determined that only TCDD and paraoxon exhibited a concentration-dependent effect on 
cardiovascular function in the absence of effects on body length. 
Using the highest concentration meeting body length and survival criteria (Figure 
3.6A), we found that chemicals were clustered by site of action, suggesting that, within 





common site of action is similar within zebrafish embryos. However, when we clustered 
chemicals based on targeted effects to the cardiovascular system (Figure 3.6B), we found 
that only two out of 10 chemicals – TCDD and paraoxon – affected the cardiovascular 
system in a concentration-dependent manner, suggesting that, despite differences in 
potency based on gross malformations, this assay has the potential to identify 
cardiovascular toxicants. 
Eight of the 10 chemicals screened did not adversely impact the cardiovascular 
system using this assay, including five chemicals we initially hypothesized to be 
‘positive’. For each chemical tested, a range of 11 concentrations based on two-fold serial 
dilutions was used to increase the probability of capturing concentration-response curves 
for survival, body length, and cardiovascular-specific endpoints. With the exception of 
nicotine and imidacloprid (both of which were non-toxic up to 50 µM, the highest 
concentration tested), all chemicals screened either decreased survival and/or body 
length, suggesting that a negative finding was not a result of minimal uptake into 
developing embryos due to high rates of chemical absorption to microplate wells or low 
rates of chemical transport across the chorion.  Rather, our negative findings for 
chemicals hypothesized to be ‘positive’ for cardiovascular toxicity may be due to 
differences in life stages (embryos vs. adults), experimental systems (whole animals vs. 
cell lines), taxa (fish vs. rodents), exposure routes (aqueous vs. non-aqueous exposure), 
and/or absence of chemical-specific sites of action within zebrafish.  Since exposure to 
nicotine and imidacloprid did not affect any of the endpoints evaluated within our assay, 
these negative findings may have been due to limited embryonic uptake and/or low 





Nonetheless, these negative results further support the conclusion that – despite chemical 
potency based on apical endpoints such as survival and body length – this assay has the 
potential to identify chemicals that target cardiovascular function. 
Within zebrafish embryos, TCDD is known to cause severe heart malformations 
such as altered looping and reduced blood flow by activating the aryl hydrocarbon 
receptor (AHR) (Antkiewicz et al., 2005; Carney et al., 2006; McGee et al., 2013).  
Similarly, in our HCS assay TCDD significantly decreased arterial circulation and 
increased pericardial area – an endpoint associated with incomplete cardiac looping – 
without significantly affecting venous circulation, heart rate, and intersegmental vessel 
area. While paraoxon is a known acetylcholinesterase (AChE) inhibitor and is often 
associated with developmental neurotoxicity (Teixido et al., 2013; Yozzo et al., 2013a), 
in our HCS assay paraoxon significantly decreased heart rate at all concentrations tested 
in the absence of effects on any other endpoints. Therefore, this paraoxon-induced effect 
on heart rate may have been undetected within cell-based systems, suggesting that 
targeted HCS assays using intact embryos provide an opportunity to reveal unexpected 
chemical MOAs.  
In summary, compared to existing zebrafish-based assays, this HCS assay 
provides a comprehensive discovery platform with sufficient power, replication, and 
exposure concentrations to screen and identify potential cardiovascular toxicants.  While 
mechanisms of toxicity were not investigated within this study, in the future this HCS 
assay can be readily coupled with reverse genetics approaches to identify the potential 
role of xenobiotic receptors in chemically-induced effects on cardiovascular development 





will significantly increase the rate of screening and prioritizing chemicals for hypothesis-
driven MOA research as well as uncover mechanisms of cardiovascular toxicity for 






Table 3.1: Image success rates for analysis of heart rate within control 72-hpf zebrafish 
embryos following a 30-minute immersion within 100-300 mg/L MS-222.  The 
percentage of embryos that were hatched and alive was relative to an initial sample size 
of 384 embryos per MS-222 concentration, whereas the percentage of embryos that were 
analyzed was relative to the number of hatched and alive embryos.  
 
Table 3.1: Image success rates for analysis of heart rate within control 72-hpf zebrafish embryos following a 30-minute immersion within 100-300 mg/L MS-222. 
 











100 352 91.7 258 73.3 
150 319 83.1 204 63.9 
200 370 96.4 197 53.2 
250 332 86.5 172 51.8 
300 315 82.0 123 39.0 
  
 
Table 3.2:  Image success rates for analysis of all endpoints within control 72-hpf zebrafish embryos across four independent plates 
containing an initial sample size of 384 embryos per plate.  The percentage of embryos that were hatched and alive was relative to an 
initial sample size of 384 embryos per MS-222 concentration, whereas the percentage of embryos that were analyzed was relative to 
the number of hatched and alive embryos. Across all five endpoints, variation in the percentage of embryos analyzed was primarily 




Hatched Length Heart Rate Pericardial Area 
Intersegmental 



























1 369 96.1 259 70.2 257 69.6 272 73.7 253 68.6 244 66.1 
2 357 93 244 68.3 244 68.3 246 68.9 228 63.9 229 64.1 
3 361 94 189 52.4 189 52.4 186 51.5 167 46.3 150 41.6 










Figure 3.1: Flow diagram summarizing the exposure setup, image acquisition, and 
endpoints for the 384-well-based HCS assay. Using automated image acquisition 
protocols and parameters optimized for our ImageXpress® Micro Widefield High-
Content Screening System, each fli1:egfp embryo was imaged to analyze the following 
endpoints: heart rate; circulation; pericardial area; body length; and intersegmental vessel 
area. 
  
Figure 7.1: Flow diagram summarizing the exposure setup, image acquisition, and endpoints 







Figure 3.2: Representative raw (left) and analyzed (right) images of vehicle-treated 
zebrafish embryos used to determine A) body length; B) heart rate; C) intersegmental 
vessel area; D) pericardial area; and E) circulation. Lines, circles, and boxes within 
analyzed images denote areas of measurement for each endpoint.  For circulation, the 
green, blue, and purple lines (black arrows) within the analyzed image denote lines used 
to quantify arterial circulation, venous circulation, and background intensity, 
respectively.   
Figure 8: 
Representat




























































Figure 3.3: Mean heart rate (± SD) of 72-hpf fli1:egfp zebrafish embryos following a 30-
minute immersion within 100-300 mg/L MS-222 (A) or every 12 minutes over a 132-
minute image acquisition period following initial immersion within 100 mg/L MS-222 
(N=22) for 30 minutes (B).  In panel A, treatments that do not share the same letter are 
significantly different (p < 0.05) from each other.  In panel B, no significant differences 
were detected across all time points. 
 
 
Figure 9: Mean (± SD) heart rate of 72-hpf fli1:egfp zebrafish embryos following a 30-min immersion within 100-300 mg/L MS-222 or or 






Figure 10: Mean body length (± SD), intersegmental vessel area (± SD), pericardial area (± SD), heart rate (± SD), arterial circulation (± SD), and venous circulation (± SD) across 




Figure 3.4: Mean body length (± SD) (A), intersegmental vessel area (± SD) (B), 
pericardial area (± SD) (C), heart rate (± SD) (D), arterial circulation (± SD) (E), and 
venous circulation (± SD) (F) across four independent control plates consisting of 384 
initial embryos per plate. N = final number of embryos analyzed per plate.  Treatments 





Figure 3.5: Decision tree for evaluation of assay performance and validity during exposure setup (Day 0), image acquisition (Day 3), 
and data extraction/analysis (Days 4-5). Criteria for survival (>70% survival) and body length (<10% decrease relative to vehicle 
controls) were developed to (1) minimize Type I and II errors and reliably identify treatment-related effects and (2) focus our analyses 











Figure 3.6: Hierarchical cluster of chemical screening data based on the highest 
concentration meeting survival and body length criteria (A) and presence or absence of a 
concentration-dependent response on the cardiovascular system at non-teratogenic 
concentrations (B). The predicted logP value for each chemical was determined using an 
interactive logP predictor tool at www.molinspiration.com/cgi-bin/properties. Supporting 
figures for all chemical screening assays as well as chemical structures are provided in 
Yozzo et al. (2013b).   
Figure 12: Hierarchical cluster of chemical screening data based on the highest concentration meeting survival and body length criteria and 









CONCLUSIONS AND FUTURE RESEARCH  
The first study (Chapter 2) demonstrated that quantitative AOPs are difficult to 
develop even during the same developmental stage (embryogenesis) within the same 
organism (zebrafish). In fact, after exposure to non-teratogenic concentrations of 
paraoxon, an adverse outcome occurring at 26 hpf did not correspond to an adverse 
outcome at 96 hpf. Currently, there is an interest in developing qualitative AOPs, where 
data is collated from the literature to predict toxic effects at other levels of biological 
organization; however, this method may be problematic. The initiating event may be the 
same across these multiple levels of biological organization but may not lead to an 
adverse outcome at the higher levels. For example, embryos developed normally even 
when AChE was significantly inhibited, thus the initiating event (AChE inhibition) did 
not necessarily cause an adverse outcome at a higher level of organization. Additionally, 
in this study, AChE was inhibited after exposure to paraoxon; however, even in the 
presence of minimal AChE activity, the frequency of spontaneous tail contractions 
(adverse outcome) was significantly higher within 26-hpf embryos exposed to paraoxon. 
This suggests that AChE inhibition is not likely the initiating event causing the adverse 
outcome of increased frequency of spontaneous tail contractions, and other initiating 





  Future studies should be conducted to investigate initiating events that may lead 
to an increase in spontaneous tail contractions. Muscarinic and nicotinic AChRs are 
present within primary motor neuron axons (Behra et al., 2002); thus paraoxon-induced 
activation of these receptors can be examined. In a preliminary study, we unsuccessfully 
attempted to increase spontaneous tail contractions by exposing zebrafish embryos to 
acetylcholine. However, after further review, the concentrations of acetylcholine we used 
were much lower than those suggested to activate these receptors (Thomas et al., 2009). 
Future studies could be conducted using higher concentrations of acetylcholine as a 
positive control, and then co-exposing the embryos to paraoxon and either scopolamine 
hydrobromide (a muscarinic antagonist) or mecamylamine hydrochloride (a nicotinic 
antagonist) to determine if exposure to paraoxon activates either receptor.  
Additional future studies could also be conducted to explore non-cholinergic 
pathways and gap junction development. Gap junctions play an important role in linking 
spinal cord neurons and propagating spontaneous electrical current-driven depolarization 
within the motor network (Saint-Amant and Drapeau, 2001); thus, the adverse outcome 
of increased spontaneous tail contractions may be mediated through improper gap 
junction development. Finally, the development of primary motoneurons could be 
examined as well using immunohistochemistry techniques; we only examined secondary 
motoneurons and found no effect after exposure to paraoxon. Since there was an adverse 
outcome during the window of development in which primary motoneurons are present, 
there may be an effect on development of these motoneurons.  
The second study (Chapter 3) demonstrated that HTS/HCS methods can been 





help fill in the gaps of hypothesized AOPs; and 3) help develop new AOPs. For example, 
in the current chemical screen, paraoxon, a known AChE inhibitor that is often associated 
with developmental neurotoxicity (Teixido et al., 2013; Yozzo et al., 2013a), was chosen 
as a “negative” reference chemical and not expected to affect cardiovascular 
development. Conversely, exposure to non-teratogenic concentrations of paraoxon 
significantly decreased heart rate at all concentrations tested in the absence of effects on 
any other endpoints. Nonetheless, these results can help support and introduce a 
cardiovascular AOP for paraoxon in addition to those developed for the nervous system 
such as the AOP described in Figure 2.6. In fact, hypothesis-driven, low-throughput 
studies could be conducted to examine the MOA of paraoxon as well as TCDD, the only 
other chemical to screen “positive” for cardiotoxicity, more closely. These follow-up 
studies can be used to fill in the gaps of key initiating events within AOPs. 
Even though the HCS assay described in Chapter 3 was successful in identifying 
chemicals that affect cardiovascular development within zebrafish embryos, there were a 
few limitations of the assay. First, the data extraction was more time consuming that we 
anticipated, making this assay more of a medium-throughput assay compared to other 
assays that can test hundreds of chemicals with a weeks time. However, this assay was 
able to rapidly produce more data compared to manual imaging procedures using a 
microscope or using immunohistochemistry methods and a confocal microscope. Second, 
due to using fluorescence as a way to quantify intersegmental vessel area, we were 
unable to screen chemicals that autofluoresce due to an increase in the background 
intensity within wells, creating a concentration-dependent increase in fluorescence that 





able to detect a difference in circulation when there was a reduction in blood cells and not 
when the blood flow was slower. Due to complications at higher magnifications, 4X 
magnification was the highest we could use to image circulation. However, at this 
magnification, the blood cells were not large enough to image individual cells, so we 
were unable to track blood cells over time to determine the velocity of circulation. After 
manually viewing each chemical screen, TCDD was the only compound to affect 
circulation, so we used FFT magnitude as a method for quantifying changes in 
circulation. Even with these few limitations, this assay can be used to screen chemicals 
and successfully identify cardiotoxicants. 
Overall, by relying on zebrafish-based developmental toxicity assays, we were 
able to develop: (1) an AOP describing the potential key initiating events that lead to the 
adverse outcome of increased spontaneous tail contractions when exposed to paraoxon; 
and (2) a high-content imaging assay that can be used to screen chemicals and 
successfully identify cardiotoxicants. Furthermore, this study highlights the challenges of 
developing quantitative AOPs. Nonetheless, qualitative AOPs can be used to help 
prioritize which chemicals should be screened within HCS. The results of these chemical 
screens can help fill gaps within current AOPs as well as facilitate the development of 
new AOPs. Chemicals can then prioritized for further testing within conventional animal 












Adams, M.D., Celniker, S.E., Holt, R.A., Evans, C.A., Gocayne, J.D., Amanatides, P.G., 
Scherer, S.E., Li, P.W., Hoskins, R.A., Galle, R.F., George, R.A., Lewis, S.E., Richards, 
S., Ashburner, M., Henderson, S.N., Sutton, G.G., Wortman, J.R., Yandell, M.D., Zhang, 
Q., Chen, L.X., Brandon, R.C., Rogers, Y.H., Blazej, R.G., Champe, M., Pfeiffer, B.D., 
Wan, K.H., Doyle, C., Baxter, E.G., Helt, G., Nelson, C.R., Gabor, G.L., Abril, J.F., 
Agbayani, A., An, H.J., Andrews-Pfannkoch, C., Baldwin, D., Ballew, R.M., Basu, A., 
Baxendale, J., Bayraktaroglu, L., Beasley, E.M., Beeson, K.Y., Benos, P.V., Berman, 
B.P., Bhandari, D., Bolshakov, S., Borkova, D., Botchan, M.R., Bouck, J., Brokstein, P., 
Brottier, P., Burtis, K.C., Busam, D.A., Butler, H., Cadieu, E., Center, A., Chandra, I., 
Cherry, J.M., Cawley, S., Dahlke, C., Davenport, L.B., Davies, P., de Pablos, B., Delcher, 
A., Deng, Z., Mays, A.D., Dew, I., Dietz, S.M., Dodson, K., Doup, L.E., Downes, M., 
Dugan-Rocha, S., Dunkov, B.C., Dunn, P., Durbin, K.J., Evangelista, C.C., Ferraz, C., 
Ferriera, S., Fleischmann, W., Fosler, C., Gabrielian, A.E., Garg, N.S., Gelbart, W.M., 
Glasser, K., Glodek, A., Gong, F., Gorrell, J.H., Gu, Z., Guan, P., Harris, M., Harris, 
N.L., Harvey, D., Heiman, T.J., Hernandez, J.R., Houck, J., Hostin, D., Houston, K.A., 
Howland, T.J., Wei, M.H., Ibegwam, C., Jalali, M., Kalush, F., Karpen, G.H., Ke, Z., 
Kennison, J.A., Ketchum, K.A., Kimmel, B.E., Kodira, C.D., Kraft, C., Kravitz, S., Kulp, 
D., Lai, Z., Lasko, P., Lei, Y., Levitsky, A.A., Li, J., Li, Z., Liang, Y., Lin, X., Liu, X., 
Mattei, B., McIntosh, T.C., McLeod, M.P., McPherson, D., Merkulov, G., Milshina, 
N.V., Mobarry, C., Morris, J., Moshrefi, A., Mount, S.M., Moy, M., Murphy, B., 
Murphy, L., Muzny, D.M., Nelson, D.L., Nelson, D.R., Nelson, K.A., Nixon, K., 
Nusskern, D.R., Pacleb, J.M., Palazzolo, M., Pittman, G.S., Pan, S., Pollard, J., Puri, V., 
Reese, M.G., Reinert, K., Remington, K., Saunders, R.D., Scheeler, F., Shen, H., Shue, 
B.C., Siden-Kiamos, I., Simpson, M., Skupski, M.P., Smith, T., Spier, E., Spradling, 
A.C., Stapleton, M., Strong, R., Sun, E., Svirskas, R., Tector, C., Turner, R., Venter, E., 
Wang, A.H., Wang, X., Wang, Z.Y., Wassarman, D.A., Weinstock, G.M., Weissenbach, 
J., Williams, S.M., WoodageT, Worley, K.C., Wu, D., Yang, S., Yao, Q.A., Ye, J., Yeh, 
R.F., Zaveri, J.S., Zhan, M., Zhang, G., Zhao, Q., Zheng, L., Zheng, X.H., Zhong, F.N., 
Zhong, W., Zhou, X., Zhu, S., Zhu, X., Smith, H.O., Gibbs, R.A., Myers, E.W., Rubin, 
G.M., Venter, J.C., 2000. The genome sequence of Drosophila melanogaster. Science 
287, 2185-2195. 
Adewusi, E., Steenkamp, V., 2011. In vitro screeing for acetylcholinesterase inhibition 
and antioxidant activity of medicinal plants from southern Africa. Asian Pacific Journal 
of Tropical Medicine, 829-835. 
Andersen, M.E., Krewski, D., 2009. Toxicity testing in the 21st century: bringing the 





Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., 
Mount, D.R., Nichols, J.W., Russom, C.L., Schmieder, P.K., Serrrano, J.A., Tietge, J.E., 
Villeneuve, D.L., 2010. Adverse outcome pathways: a conceptual framework to support 
ecotoxicology research and risk assessment. Environ Toxicol Chem 29, 730-741. 
Antkiewicz, D.S., Burns, C.G., Carney, S.A., Peterson, R.E., Heideman, W., 2005. Heart 
malformation is an early response to TCDD in embryonic zebrafish. Toxicol Sci 84, 368-
377. 
Arduini, F., Errico, I., Amine, A., Micheli, L., Palleschi, G., Moscone, D., 2007. 
Enzymatic spectrophotometric method for aflatoxin B detection based on 
acetylcholinesterase inhibition. Anal Chem 79, 3409-3415. 
Baek, J.H., Cosman, P., Feng, Z., Silver, J., Schafer, W.R., 2002. Using machine vision 
to analyze and classify Caenorhabditis elegans behavioral phenotypes quantitatively. J 
Neurosci Methods 118, 9-21. 
Bakkers, J., 2011. Zebrafish as a model to study cardiac development and human cardiac 
disease. Cardiovasc Res 91, 279-288. 
Behra, M., Cousin, X., Bertrand, C., Vonesch, J.L., Biellmann, D., Chatonnet, A., 
Strahle, U., 2002. Acetylcholinesterase is required for neuronal and muscular 
development in the zebrafish embryo. Nat Neurosci 5, 111-118. 
Belanger, S., Balon, E., Rawlings, J.M., 2010. Saltatory ontogeny of fishes and sensitive 
early life stages for ecotoxicology tests. Aquat Toxicol 97, 88-95. 
Bertrand, C., Chatonnet, A., Takke, C., Yan, Y., Postlethwait, J., Toutant, J., Cousin, X., 
2001. Zebrafish acetylcholinesterase is encoded by a single gene localized on linkage 
group 7. J Biol Chem 276, 464-474. 
Blader, P., Strahle, U., 2000. Zebrafish developmental genetics and central nervous 
system development. Hum Mol Genet 9, 945-951. 
Boyd, W.A., Smith, M.V., Kissling, G.E., Freedman, J.H., 2010. Medium- and high-
throughput screening of neurotoxicants using C. elegans. Neurotoxicol Teratol 32, 68-73. 
Bradbury, S.P., Feijtel, T.C., Van Leeuwen, C.J., 2004. Meeting the scientific needs of 
ecological risk assessment in a regulatory context. Environ Sci Technol 38, 463A-470A. 
Branson, K., Robie, A.A., Bender, J., Perona, P., Dickinson, M.H., 2009. High-
throughput ethomics in large groups of Drosophila. Nat Methods 6, 451-457. 
Brustein, E., Saint-Amant, L., Buss, R., Chong, M., McDearmid, J., Drapeau, P., 2003. 





Burns, C.G., Milan, D.J., Grande, E.J., Rottbauer, W., MacRae, C.A., Fishman, M.C., 
2005. High-throughput assay for small molecules that modulate zebrafish embryonic 
heart rate. Nat Chem Biol 1, 263-264. 
Carney, S.A., Chen, J., Burns, C.G., Xiong, K.M., Peterson, R.E., Heideman, W., 2006. 
Aryl hydrocarbon receptor activation produces heart-specific transcriptional and toxic 
responses in developing zebrafish. Mol Pharmacol 70, 549-561. 
Casarett, L.J., Doull, J., Klaassen, C.D., 2008. Casarett and Doull's toxicology : the basic 
science of poisons, 7th ed. McGraw-Hill, New York. 
Childs, S., Chen, J.N., Garrity, D.M., Fishman, M.C., 2002. Patterning of angiogenesis in 
the zebrafish embryo. Development 129, 973-982. 
Correll, L., Ehrich, M., 1991. A microassay method for neurotoxic esterase 
determinations. Fundam Appl Toxicol 16, 110-116. 
Corsi, A.K., 2006. A biochemist's guide to Caenorhabditis elegans. Anal Biochem 359, 1-
17. 
Dankert, H., Wang, L., Hoopfer, E.D., Anderson, D.J., Perona, P., 2009. Automated 
monitoring and analysis of social behavior in Drosophila. Nat Methods 6, 297-303. 
Dix, D.J., Houck, K.A., Martin, M.T., Richard, A.M., Setzer, R.W., Kavlock, R.J., 2007. 
The ToxCast program for prioritizing toxicity testing of environmental chemicals. 
Toxicol Sci 95, 5-12. 
Downes, G.B., Granato, M., 2004. Acetylcholinesterase function is dispensable for 
sensory neurite growth but is critical for neuromuscular synapse stability. Dev Biol 270, 
232-245. 
Ellman, G., Courtney, K., Andres Jr, V., Featherstone, R., 1961. A new and rapid 
colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7, 88-95. 
Embry, M.R., Belanger, S.E., Braunbeck, T.A., Galay-Burgos, M., Halder, M., Hinton, 
D.E., Leonard, M.A., Lillicrap, A., Norberg-King, T., Whale, G., 2010. The fish embryo 
toxicity test as an animal alternative method in hazard and risk assessment and scientific 
research. Aquat Toxicol 97, 79-87. 
Fitzmaurice, A.G., Rhodes, S.L., Lulla, A., Murphy, N.P., Lam, H.A., O'Donnell, K.C., 
Barnhill, L., Casida, J.E., Cockburn, M., Sagasti, A., Stahl, M.C., Maidment, N.T., Ritz, 
B., Bronstein, J.M., 2013. Aldehyde dehydrogenase inhibition as a pathogenic 
mechanism in Parkinson disease. Proc Natl Acad Sci U S A 110, 636-641. 
Flamme, I., Frolich, T., Risau, W., 1997. Molecular mechanisms of vasculogenesis and 





Gasque, G., Conway, S., Huang, J., Rao, Y., Vosshall, L.B., 2013. Small molecule drug 
screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target. Sci 
Rep 3, srep02120. 
Giacomotto, J., Segalat, L., 2010. High-throughput screening and small animal models, 
where are we? Br J Pharmacol 160, 204-216. 
Glickman, N.S., Yelon, D., 2002. Cardiac development in zebrafish: coordination of form 
and function. Semin Cell Dev Biol 13, 507-513. 
Gosai, S.J., Kwak, J.H., Luke, C.J., Long, O.S., King, D.E., Kovatch, K.J., Johnston, 
P.A., Shun, T.Y., Lazo, J.S., Perlmutter, D.H., Silverman, G.A., Pak, S.C., 2010. 
Automated high-content live animal drug screening using C. elegans expressing the 
aggregation prone serpin alpha1-antitrypsin Z. PLoS One 5, e15460. 
Halder, M., Leonard, M., Iguchi, T., Oris, J.T., Ryder, K., Belanger, S.E., Braunbeck, 
T.A., Embry, M.R., Whale, G., Norberg-King, T., Lillicrap, A., 2010. Regulatory aspects 
on the use of fish embryos in environmental toxicology. Integr Environ Assess Manag 6, 
484-491. 
Hanneman, E., Trevarrow, B., Metcalfe, W.K., Kimmel, C.B., Westerfield, M., 1988. 
Segmental pattern of development of the hindbrain and spinal cord of the zebrafish 
embryo. Development 103, 49-58. 
Hanneman, E., Westerfield, M., 1989. Early expression of acetylcholinesterase activity in 
functionally distinct neurons of the zebrafish. J Comp Neurol 284, 350-361. 
Harris, T.W., Chen, N., Cunningham, F., Tello-Ruiz, M., Antoshechkin, I., Bastiani, C., 
Bieri, T., Blasiar, D., Bradnam, K., Chan, J., Chen, C.K., Chen, W.J., Davis, P., Kenny, 
E., Kishore, R., Lawson, D., Lee, R., Muller, H.M., Nakamura, C., Ozersky, P., 
Petcherski, A., Rogers, A., Sabo, A., Schwarz, E.M., Van Auken, K., Wang, Q., Durbin, 
R., Spieth, J., Sternberg, P.W., Stein, L.D., 2004. WormBase: a multi-species resource for 
nematode biology and genomics. Nucleic Acids Res 32, D411-417. 
Herbert, S.P., Huisken, J., Kim, T.N., Feldman, M.E., Houseman, B.T., Wang, R.A., 
Shokat, K.M., Stainier, D.Y., 2009. Arterial-venous segregation by selective cell 
sprouting: an alternative mode of blood vessel formation. Science 326, 294-298. 
Hill, A.J., Teraoka, H., Heideman, W., Peterson, R.E., 2005. Zebrafish as a model 
vertebrate for investigating chemical toxicity. Toxicol Sci 86, 6-19. 
Hjorth, J., Key, B., 2002. Development of axon pathways in the zebrafish central nervous 
system. Int J Dev Biol 46, 609-619. 





Ingebretson, J.J., Masino, M.A., 2013. Quantification of locomotor activity in larval 
zebrafish: considerations for the design of high-throughput behavioral studies. Front 
Neural Circuits 7, 109. 
Isogai, S., Horiguchi, M., Weinstein, B.M., 2001. The vascular anatomy of the 
developing zebrafish: an atlas of embryonic and early larval development. Dev Biol 230, 
278-301. 
Jacobson, S., Birkholz, D., McNamara, M., Bharate, S., George, K., 2010. Subactue 
developmental exposure of zebrafish to the organophosphate pesticide metabolite, 
chlorypyrifos-oxon, results in defects in Rohon-Beard sensory neuron development. 
Aquat Toxicol 100, 101-111. 
Jakubowski, B.R., Longoria, R.A., Shubeita, G.T., 2012. A high throughput and sensitive 
method correlates neuronal disorder genotypes to Drosophila larvae crawling phenotypes. 
Fly (Austin) 6, 303-308. 
Jiang, W., Duysen, E.G., Lockridge, O., 2012. Mice treated with a nontoxic dose of 
chlorpyrifos oxon have diethoxyphosphotyrosine labeled proteins in blood up to 4 days 
post exposure, detected by mass spectrometry. Toxicology 295, 15-22. 
Jin, S.W., Beis, D., Mitchell, T., Chen, J.N., Stainier, D.Y., 2005. Cellular and molecular 
analyses of vascular tube and lumen formation in zebrafish. Development 132, 5199-
5209. 
Katz, E.J., Cortes, V.I., Eldefrawi, M.E., Eldefrawi, A.T., 1997. Chlorpyrifos, parathion, 
and their oxons bind to and desensitize a nicotinic acetylcholine receptor: relevance to 
their toxicities. Toxicol Appl Pharmacol 146, 227-236. 
Kimmel, C., Patterson, J., Kimmel, R., 1972. The development and behavioral 
characteristics of the startle response in zebra fish. Dev Psychobiol 7, 47-60. 
Kimmel, C.B., 1993. Patterning the brain of the zebrafish embryo. Annu Rev Neurosci 
16, 707-732. 
Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., Schilling, T.F., 1995. Stages 
of embryonic development of the zebrafish. Dev Dyn 203, 253-310. 
Kleinstreuer, N.C., Judson, R.S., Reif, D.M., Sipes, N.S., Singh, A.V., Chandler, K.J., 
Dewoskin, R., Dix, D.J., Kavlock, R.J., Knudsen, T.B., 2011. Environmental impact on 
vascular development predicted by high-throughput screening. Environ Health Perspect 
119, 1596-1603. 
Kluver, N., Yang, L., Busch, W., Scheffler, K., Renner, P., Strahle, U., Scholz, S., 2011. 
Transcriptional response of zebrafish embryos exposed to neurotoxic compounds reveals 





Kuster, E., 2005. Cholin- and carboxylesterase activities in developing zebrafish embryos 
(Danio rerio) and their potential use for insecticide hazard assessment. Aquat Toxicol 75, 
76-85. 
Kuster, E., Altenburger, R., 2006. Comparison of cholin- and carboxylesterase enzyme 
inhibition and visible effects in the zebra fish embryo bioassay under short-term 
paraoxon-methyl exposure. Biomarkers 11, 341-354. 
Kuwada, J.Y., Bernhardt, R.R., Nguyen, N., 1990. Development of spinal neurons and 
tracts in the zebrafish embryo. J Comp Neurol 302, 617-628. 
Langheinrich, U., 2003. Zebrafish: a new model on the pharmaceutical catwalk. 
Bioessays 25, 904-912. 
Lawson, N.D., Weinstein, B.M., 2002. In vivo imaging of embryonic vascular 
development using transgenic zebrafish. Dev Biol 248, 307-318. 
Leung, M.C., Williams, P.L., Benedetto, A., Au, C., Helmcke, K.J., Aschner, M., Meyer, 
J.N., 2008. Caenorhabditis elegans: an emerging model in biomedical and environmental 
toxicology. Toxicol Sci 106, 5-28. 
Lieschke, G.J., Currie, P.D., 2007. Animal models of human disease: zebrafish swim into 
view. Nat Rev Genet 8, 353-367. 
Lin, S., Zhao, Y., Ji, Z., Ear, J., Chang, C.H., Zhang, H., Low-Kam, C., Yamada, K., 
Meng, H., Wang, X., Liu, R., Pokhrel, S., Madler, L., Damoiseaux, R., Xia, T., Godwin, 
H.A., Lin, S., Nel, A.E., 2013. Zebrafish high-throughput screening to study the impact 
of dissolvable metal oxide nanoparticles on the hatching enzyme, ZHE1. Small 9, 1776-
1785. 
McCurley, A.T., Callard, G.V., 2008. Characterization of housekeeping genes in 
zebrafish: male-female differences and effects of tissue type, developmental stage and 
chemical treatment. BMC Mol Biol 9, 102. 
McGee, S.P., Konstantinov, A., Stapleton, H.M., Volz, D.C., 2013. Aryl phosphate esters 
within a major PentaBDE replacement product induce cardiotoxicity in developing 
zebrafish embryos: potential role of the aryl hydrocarbon receptor. Toxicol Sci 133, 144-
156. 
McGrath, P., Li, C.Q., 2008. Zebrafish: a predictive model for assessing drug-induced 
toxicity. Drug Discov Today 13, 394-401. 
Mirat, O., Sternberg, J.R., Severi, K.E., Wyart, C., 2013. ZebraZoom: an automated 
program for high-throughput behavioral analysis and categorization. Front Neural 
Circuits 7, 107. 
Myers, P.Z., Eisen, J.S., Westerfield, M., 1986. Development and axonal outgrowth of 





National Institute of Health, Guidelines for use of zebrafish in the NIH Intramural 
Reserach Program. http://oacu.od.nih.gov/ARAC/documents/Zebrafish.pdf.  
NRC, 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. National 
Academies Press, Washington, DC. 
OECD, 2012. Guidance document on developing and assessing Adverse Outcome 
Pathways. 
Padilla, S., Corum, D., Padnos, B., Hunter, D.L., Beam, A., Houck, K.A., Sipes, N., 
Kleinstreuer, N., Knudsen, T., Dix, D.J., Reif, D.M., 2012. Zebrafish developmental 
screening of the ToxCast Phase I chemical library. Reprod Toxicol 33, 174-187. 
Peng, H., Long, F., Zhou, J., Leung, G., Eisen, M.B., Myers, E.W., 2007. Automatic 
image analysis for gene expression patterns of fly embryos. BMC Cell Biol 8 Suppl 1, 
S7. 
Pope, C.N., 1999. Organophosphorus pesticides: do they all have the same mechanism of 
toxicity? J Toxicol Environ Health B Crit Rev 2, 161-181. 
REACH, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 
22 September 2010 on the Protection of Animals Used for Scientific Purposes. 
Renquist, B.J., Zhang, C., Williams, S.Y., Cone, R.D., 2013. Development of an assay 
for high-throughput energy expenditure monitoring in the zebrafish. Zebrafish 10, (3), 
343-352. 
Saint-Amant, L., Drapeau, P., 1998. Time course of the development of motor behaviors 
in the zebrafish embryo. Journal of Neurobiology 37, 622-632. 
Saint-Amant, L., Drapeau, P., 2000. Motoneuron activity patterns related to the earliest 
behavior of the zebrafish embryo. J Neurosci 20, 3964-3972. 
Saint-Amant, L., Drapeau, P., 2001. Synchronization of an embryonic network of 
identified spinal interneurons solely by electrical coupling. Neuron 31, 1035-1046. 
Schmidt, C.W., 2009. TOX 21: new dimensions of toxicity testing. Environ Health 
Perspect 117, A348-353. 
Scholz, S., Fischer, S., Gundel, U., Kuster, E., Luckenbach, T., Voelker, D., 2008. The 
zebrafish embryo model in environmental risk assessment--applications beyond acute 
toxicity testing. Environ Sci Pollut Res Int 15, 394-404. 
Spomer, W., Pfriem, A., Alshut, R., Just, S., Pylatiuk, C., 2012. High-throughput 
screening of zebrafish embryos using automated heart detection and imaging. J Lab 





Stainier, D.Y., Lee, R.K., Fishman, M.C., 1993. Cardiovascular development in the 
zebrafish. I. Myocardial fate map and heart tube formation. Development 119, 31-40. 
Teixido, E., Pique, E., Gomez-Catalan, J., Llobet, J.M., 2013. Assessment of 
developmental delay in the zebrafish embryo teratogenicity assay. Toxicol In Vitro 27, 
469-478. 
Thomas, L.T., Welsh, L., Galvez, F., Svoboda, K.R., 2009. Acute nicotine exposure and 
modulation of a spinal motor circuit in embryonic zebrafish. Toxicol Appl Pharmacol 
239, 1-12. 
Tran, T.C., Sneed, B., Haider, J., Blavo, D., White, A., Aiyejorun, T., Baranowski, T.C., 
Rubinstein, A.L., Doan, T.N., Dingledine, R., Sandberg, E.M., 2007. Automated, 
quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. 
Cancer Res 67, 11386-11392. 
Trevarrow, B., Marks, D.L., Kimmel, C.B., 1990. Organization of hindbrain segments in 
the zebrafish embryo. Neuron 4, 669-679. 
U.S. EPA, 2000. Chlorpyrifos Revised Risk Assessment and Agreement with Registrants. 
Washington, DC: U.S. Environmental Protection Agency. 
U.S. EPA, 2001. Diazinon Revised Risk Assessment and Agreement with Registrants. 
Washington, DC: U.S. Environmental Protection Agency. 
Veneman, W.J., Stockhammer, O.W., de Boer, L., Zaat, S.A., Meijer, A.H., Spaink, H.P., 
2013. A zebrafish high throughput screening system used for Staphylococcus epidermidis 
infection marker discovery. BMC Genomics 14, 255. 
Villeneuve, D.L., Garcia-Reyero, N., 2011. Vision & strategy: Predictive ecotoxicology 
in the 21st century. Environ Toxicol Chem 30, 1-8. 
Wen, D., Liu, A., Chen, F., Yang, J., Dai, R., 2012. Validation of visualized transgenic 
zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk 
candidates. J Appl Toxicol 32, 834-842. 
Westerfield, M., McMurray, J.V., Eisen, J.S., 1986. Identified motoneurons and their 
innervation of axial muscles in the zebrafish. J Neurosci 6, 2267-2277. 
Wilson, S.W., Ross, L.S., Parrett, T., Easter, S.S., Jr., 1990. The development of a simple 
scaffold of axon tracts in the brain of the embryonic zebrafish, Brachydanio rerio. 
Development 108, 121-145. 
Yang, D., Lauridsen, H., Buels, K., Chi, L., La Du, J., Bruun, D., Olson, J., Tanguay, R., 
Lein, P., 2011. Chlorpyrifos-oxon disrupts zebrafish axonal growth and motor behavior. 





Yen, J., Donerly, S., Levin, E., Linney, E., 2011. Differential acetylcholinesterase 
inhibition of chlorpyrifos, diazinon and parathion in larval zebrafish. Neurotoxicology 
and Teratology 33, 735-741. 
Yozzo, K.L., McGee, S.P., Volz, D.C., 2013a. Adverse outcome pathways during 
zebrafish embryogenesis: a case study with paraoxon. Aquat Toxicol 126, 346-354. 
Yozzo, K.L., Isales, G.M., Raftery, T.D., Volz, D.C., 2013b. High-content screening 
assay for identification of chemicals impacting cardiovascular function in zebrafish 
embryos. Environ Sci Technol 19, 11302-11310. 
Zon, L.I., Peterson, R.T., 2005. In vivo drug discovery in the zebrafish. Nat Rev Drug 












APPENDIX A: SUPPLEMENTAL TABLE 
 
Table A.1: Chemical name, chemical formula, CAS registry number, vendor, and purity 
of all chemicals screened. 





Formula CAS # Vendor 
Purity 
(%) 
CL-4AS-1 C26H33ClN2O2 188589-66-4 Tocris Bioscience >99.7 
Cypermethrin C22H19Cl2NO3 52315-07-8 ChemService Inc. 99.0 
Endosulfan C9H6Cl6O3S 115-29-7 ChemService Inc. 99.0 
17B-Estradiol C18H24O2  50-28-2 Tocris Bioscience 99.0 
Genistein C15H10O5 446-72-0 Tocris Bioscience >98.0 
Imidacloprid C9H10ClN5O2 138261-41-3 ChemService Inc. 99.5 
Nicotine C10H14N2  54-11-5 ChemService Inc. 99.2 
Paraoxon C10H14NO6P  311-45-5 ChemService Inc. 97.5 
Pyridaben C19H25ClN2OS 96489-71-3 ChemService Inc. 99.5 
2,3,7,8-TCDD C12H4Cl4O2 1746-01-6 Cambridge Isotope Libraries, Inc. 99.2 
  
 
 
 
